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Breast cancer is the most common cancer in women worldwide. The molecular 
mechanisms underlying the disease have been extensively studied, leading to dramatic 
improvements in diagnostic and prognostic approaches. Despite the overall 
improvements in survival rate, numerous cases of death by breast cancer are still 
reported per year, alerting us about the potential gap of knowledge in cancer molecular 
biology era. The emerging advances in new generation sequencing techniques have 
revealed that the majority of genome is transcribed into non-protein coding RNAs 
(ncRNAs), including thousands of long ncRNAs (lncRNAs). At present, we do not know 
the biological function of majority of these lncRNAs.  
MALAT1 (metastasis associated lung adenocarcinoma transcript1) is a lncRNA which its 
expression is deregulated in various tumors, including breast cancer. However, the 
significance of such abnormal expression is yet to be fully understood. In this study, we 
demonstrate that regulation of aggressive breast cancer cell traits by MALAT1 is not 
predicted solely based on an elevated expression level but is context specific. By 
performing loss- and gain-of-function studies, both under in vitro and in vivo conditions, 
we demonstrate that MALAT1 facilitates cell proliferation, tumor progression and 
metastasis of triple-negative breast cancer (TNBC) cells despite having a comparatively 
lower expression level than ER or HER2-positive breast cancer cells. Furthermore, 
MALAT1 regulates the expression of several cancer metastasis-related genes, but 
displays molecular subtype specific correlations with such genes. Assessment of the 
prognostic significance of MALAT1 in human breast cancer (n=1992) revealed elevated 
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MALAT1 expression was associated with decreased disease-specific survival in ER 
negative, lymph node negative patients of the HER2 and TNBC molecular subtypes. 
Multivariable analysis confirmed MALAT1 to have independent prognostic significance 
in the TNBC lymph node negative patient subset (HR=2.64, 95%CI 1.35- 5.16, p=0.005). 
We propose that the functional significance of MALAT1 as a metastasis driver and its 
potential use as a prognostic marker is most promising for those patients diagnosed 
with ER negative, lymph node negative breast cancer who might otherwise mistakenly 
be stratified to have low recurrence risk. 
Next, to expand our insights into the role of lncRNAs in breast cancer progression, we 
performed genome-wide transcriptome analyses in an isogenic, triple negative breast 
cancer (TNBC/basal-like) progression cell lines using a 3D cell culture model. We 
identified aberrant expression of ~2900 lncRNAs, including ~1000 natural antisense 
transcript (NATs) lncRNAs. A significant number of breast cancer-deregulated NATs 
displayed co-regulated expression with oncogenic and tumor suppressor protein-coding 
genes in cis. Further studies on one such NAT, PDCD4-AS1 lncRNA reveal that it 
positively regulates the expression and activity of the tumor suppressor PDCD4 in TNBC. 
Both PDCD4-AS1 and PDCD4 show reduced expression in TNBC cell lines and in patients, 
and depletion of PDCD4-AS1 compromise the cellular levels and activity of PDCD4. 
Further, tumorigenic properties of PDCD4-AS1-depleted TNBC cells were rescued by 
exogenous expression of PDCD4, implying that PDCD4-AS1 acts upstream of PDCD4. Our 
results reveal that PDCD4-AS1 stabilizes PDCD4 RNA by forming an RNA duplex, and 
controls the interaction between PDCD4 RNA and RNA decay promoting factors such as 
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HuR, thereby stabilizing PDCD4 mRNA. Our studies demonstrate crucial roles played by 
NAT lncRNAs in regulating post-transcriptional gene expression of key oncogenic or 
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CHAPTER 1. INTRODUCTION 
1.1 Breast Cancer (BC) 
Breast Cancer (BC) is the most common cancer comprising 25% of all cancer cases in 
women [1]. BC is one of the most ancient diseases reported in the history of medicine, 
first dating back to ancient Egypt. One of the first evidences reporting of breast cancer is 
the Egyptian papyrus of Edwin Smith from 1600BC [2]. At that time, breast cancer was 
described as an incurable disease.  Following medical development, physicians came up 
with idea of staging the disease and removing the tumor [3-7]. The breast cancer 
surgical treatment was mainly flourished upon progress in surgical procedures; 
particularly anesthesia development and disinfection [8]. Along with dramatic 
improvements in surgery, radiotherapy, chemotherapy and endocrine therapy that were 
developed later in the modern era of medicine in the 20th century, the survival rate of 
BC patients increased significantly [3, 9, 10].  
Presently, the survival rate is relatively high, particularly in developed countries, with 80 
to 90% of patients surviving more than 5 years after the initial diagnosis [1]. However, in 
2012, ~1.68 million new cases and 522,000 deaths were reported all around the world, 
implying a fundamental need for further research and development of more efficient 
treatment strategies [11].  
1.1.1 Breast Cancer (BC) Classification 
The emergence of high throughput technologies such as microarray in the 21st century 
acted as a watershed moment in cancer research, leading to identification of breast 
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cancer intrinsic molecular subtypes based on gene expression profiling. Molecular 
profiling was a breakthrough in cancer research with better relevance to therapeutic 
vulnerabilities; a step closer to personalized therapy considering the stage of the 
disease, the molecular profile, and genetic background in each patient individual [12, 
13]. The molecular breast cancer taxonomy is primarily based on the presence or 
absence of three hormone receptors; estrogen receptor (ER), progesterone receptor 
(PR) and human epidermal growth factor receptor 2 (HER2). Based on which hormone 
receptors are present, breast cancer samples are grouped into subtypes such as Luminal 
A (ER positive and/or PR positive and HER2 negative), Luminal B (ER positive and/or PR 
positive and HER2 negative or positive), HER2+ (ER and PR negative, HER2 positive) and 
triple negative (ER/PR/HER2 negative).  
Among all, Luminal A has the best prognosis and shows low cell proliferation (low Ki-67 
protein, which is a marker for cell proliferation), low grade and high sensitivity to 
endocrine treatment. Luminal B has worse prognosis as it shows more proliferative 
characteristics (high Ki-67) and moderate response to endocrine treatment. HER2 
subtype is very fast growing and aggressive tumor, but responds very well to therapies 
targeting HER2 receptor. Triple negative breast cancer (TNBC) subtype is common in 
young women, especially those with BRCA1 gene mutation. Among all types, TNBC has 
the worst prognosis as TNBC patients do not respond well to hormone therapy due to 
receptor negativity for all three hormone receptors [12-15]. Therefore, there is an 
emergent need to further investigate BC different subtypes particularly TNBC subtype to 
come up with efficient prognostic and diagnostic markers.  
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1.1.2 Breast Cancer Molecular Biology 
In general; cancer could be characterized with “six hallmarks”: a) highly active 
proliferative signaling; b) insensitivity to growth inhibitory signals; c) evading cell death; 
d) replicative immortality; e) triggering angiogenesis; and f) high mobility and 
invasiveness leading to migration and metastasis. Two more hallmarks could be 
amended to the above list as: g) customized energy metabolism; and h) escaping 
immune system [16]. The acquisition of these hallmarks is a consequence of genome 
instability and deregulation in gene expression in cancer cells, which necessitate the 
research on the molecular biology behind this deregulation. 
Gene expression profiling and copy number analysis have identified several copy 
number aberrations (CNA) in breast cancer intrinsic subtypes [17, 18]. For example, in 
the case of HER2+ subtype, there is a high level amplification in chromosome 17, q arm 
where HER2 (ERBB2) gene is located. In addition to increase or/and decrease in copy 
number, there are several recurrent gene mutations observed in each molecular 
subtype. The top 5 gene mutations reported in each subtype is as follows: PIK3CA (45%), 
GATA3 (14%), MAP3K1 (13%), TP53 (12%), CDH1 (9%) in Luminal A; TP53 (29%), PIK3CA 
(29%), GATA3 (15%), MLL3 (6%), MAP3K1 (5%) in Luminal B; TP53 (72%), PIK3CA (39%), 
MLL3 (7%), AFF2 (5%), PTPN22 (5%) in HER2+; and TP53 (80%), PIK3CA (9%), MLL3 (5%), 
RB1 (4%), AFF2 (4%) in TNBC [3, 17, 18].  
In addition to identification of copy number aberrations and gene mutations, high 
throughput gene screening adds another layer of information as so-called first 
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generation prognostic gene signatures. These prognostic gene signatures are currently 
of clinical help to a more accurate evaluation of the disease and a better prediction of 
the clinical outcome and behavior [3, 19]. These multi-gene prognostic signatures are 
available in multiple forms, such as MapQuant DX (97 genes), MammaPrint (70 genes), 
PAM50 (50 genes), Oncotype DX (21 genes), Endopredict (8 genes), and Theros (2 genes) 
[3].   
Considering the evidence indicating the importance of the interaction between the 
tumor, the surrounding stroma and immune system, there are also some second 
generation stroma-derived and immune-related prognostic signatures available, such as 
SDPP (26 genes) and CD10+ (12 genes) [20-24]. However, the clinical application of the 
second generation signature still needs more clinical confirmation.  
1.1.3 Breast Cancer Treatment 
Nowadays, breast cancer treatment is opted based on the subtype, which each patient 
fits in  [3]. In general, breast cancer patients benefit from surgery, radiotherapy and 
chemotherapy. In particular, hormone receptor positive subtypes such as Luminal A 
respond to endocrine treatment such as Tamoxifen [25]. Luminal B breast cancer is 
vulnerable to endocrine treatment plus cytotoxic chemotherapy [26]. HER2+ patients 
are responsive to treatment with HER2-blocking agents such as Herceptin 
(trastuzumab), Perjeta (pertuzumab), Tykerb (lapatinib), and Kadcyla (T-DM1) [15]. 
TNBC patients benefit from cytotoxic chemotherapy, but they still suffer from the lack of 
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an effective treatment [27]. Nonetheless, there are still several cases in each subtype, 
which show resistance to respective treatments. 
 A better understanding of the molecular biology underlying breast cancer and a more 
detailed stratification is still required for a more precise treatment. Further insight into 
the molecular mechanism of the disease and its genetic aberrations may enable us to 
identify better prognostic and diagnostic markers and more effective treatment. In this 
thesis, the molecular pathway underlying breast cancer disease is investigated focusing 
on the TNBC subtype and a novel class of gene regulatory biomolecules called long non-
coding RNAs.  
1.2 Long Non-Coding RNAs (LncRNAs) 
It is fascinating that all the cells in our body share the same set of DNA. In fact, rather 
than DNA content, the diversity of cells comes from a differential gene expression and 
the complex regulation governing the gene expression. Any disruption in gene 
expression pattern may trigger abnormalities and diseases as fatal as cancer. For a long 
time the gene expression research was focused on traditional ‘central dogma of 
biology’. The ‘Central dogma of biology’ explains that DNA is the main genetic content of 
cell, which dictates the gene expression program in each individual cell. DNA is 
transcribed to RNA, and then RNA acts as messenger and a template for translating the 
counterpart protein. Finally, proteins have been perceived as the main functional unit of 
any biological processes in the classic ‘central dogma of biology’.  
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However, modern gene expression analyses indicate that while more than 80% of the 
genome is transcribed to RNA, only 2% of this transcribed RNA is translated into 
proteins. Therefore, there is a huge number of non-(protein)-coding RNAs (ncRNAs) 
available in cells, implicating the potential necessity of this high transcription activity 
rather than just being a collateral and noise expression [28-31]. The revolutionary 
discovery of a class of non-coding RNAs called microRNAs (miRNAs) with vast impact on 
regulating the expression of numerous protein-coding genes further proved that we 
need a transition from the solely protein-centered biology to a more comprehensive 
version, including these new players;  “non-coding RNAs” to understand the complexity 
of biology [32, 33]. 
Non-coding RNA is a general class of all RNAs that do not encode for any proteins. 
However, non-coding RNAs are grouped into different subclasses; from short non-
coding transcripts like miRNAs and piRNAs with lengths between 20-30 bp, to middle 
range ncRNAs like snRNAs and snoRNAs between 30-200 bp, and finally the long non-
coding RNAs with more than 200 bp in length. So far, the most studied class is miRNAs, 
the RNAs in short length, which function in a silencing machinery either by inhibiting 
translation of target genes or destabilizing the existing mRNAs [32, 33]. And the least is 
known about the long-non coding RNAs, the focus of this thesis.  
The story of long non-coding RNAs gained significant attention when several studies 
reported the tissue-specific expression of lncRNAs; reflecting a complicated regulation 
behind the synthesis of lncRNAs in different cell types and tissues [34-37]. In addition to 
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tissue-specific pattern, deregulation of lncRNAs have been widely reported in diseases 
such as cancer [38-41].  
Like protein coding genes, most of the lncRNAs are transcribed by RNA polymerase II, 
could be spliced and poly-adenylated [42], and contain similar chromatin marks at their 
gene regulatory elements such as promoters and enhancers [43]. However, lncRNAs in 
general show low abundance, less conservation and higher tissue specificity compared 
to protein coding genes [36, 37, 44]. 
1.2.1 LncRNAs Function and Categorization 
According to the latest GENCODE version (GRCh38, October 2016), there are 15778 
lncRNAs genes with 27720 RNA transcripts identified in human cells [45]. This enormous 
number of non-coding RNAs raises more excitement by the observation that the size of 
non-protein coding genome is correlated with eukaryotic complexity far better than the 
size of protein-coding genome during metazoan evolution [46]. Unlike miRNAs, long-non 
coding RNAs are very diverse in function, localization, abundance and interacting 
partners [47]. LncRNAs are able to make a 3D secondary structure with a capacity of 
binding to proteins as well as to nucleic acids. This dual capacity makes lncRNAs an ideal 
regulator in protein-nucleic acid network.  
Although lncRNA is a generic term based on the size of more than 200bp, there could be 
a more detailed sub-categorization based on the function, the mechanism of action and 
the genomic organization. 
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Based on some of the well-established functions, lncRNAs could be classified as: a) 
lncRNAs with effects on chromatin and DNA interactions (eg. XIST, Braveheart, Mira, 
Fendrr, Khps1, TARID, SLNCR1, TUNA, RMST, LUNAR and DEANR1); b) lncRNAs with 
effects on mRNA stability and processing (eg. LincRNA-p21, Pnky, LncND, LINC00152 and 
lncARSR); and c) lncRNAs with effects on protein stability and function (eg. lnc-DC, FAL1, 
PVT1, lncRNA-LET, LINK-A, MAYA, SAMMSON, NORAD and LINP1); for review please see 
[47]. 
Based on the mode of action, lncRNAs can be categorized as: a) decoy lncRNAs (e.g. 
ZFAS); b) signal lncRNAs (e.g. lincRNA-p21); c) guide lncRNAs (e.g. HOTAIR); and d) 
scaffold lncRNAs (e.g. ANRIL); for review please see [48]. 
Based on the genomic context, lncRNAs can be identified as: a) promoter‐associated 
lncRNAs (e.g. PANDA); b) enhancer‐associated lncRNAs (e.g.Evf2); c) natural antisense 
transcripts (e.g. HIF1A‐AS2); d) gene body associated (sense) lncRNAs (e.g. ecCEBPA); 
and e) long intergenic ncRNAs (lincRNA, e.g. HOTAIR and MALAT1) [45]. 
1.2.2 LncRNAs in Cancer 
There are ever increasing number of reports describing the deregulation of lncRNAs in a 
variety of cancers such as lung, liver, pancreatic, renal, colorectal, gastric, brain, ovarian, 
bladder, prostate and breast cancer. There are lncRNAs with potential oncogenic 
functions, which are up-regulated in cancer such as MALAT1, HOTAIR, NEAT1, ANRIL, 
H19, HOTTIP, XIST and TUG1.  And there are lncRNAs with potential tumor suppressor 
functions, which are down-regulated in cancer such as GAS5, MEG3, NBAT1, TERRA, 
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DLEU1/2, BGL3 and FER1L4. Particularly, lncRNAs such as GAS5, TERRA, HOTAIR, ANRIL, 
DANCER, NEAT1, HIF1A-AS, ZFAS, XIST, HOTAIRM1, TOPORS-AS and LSINCT have been 
reported to be associated with breast cancer. For example, oncogenic ZFAS1 acts as a 
sponge of miR-150, and induces cell proliferation. Another example is the tumor 
suppressor lncRNA MEG3, which contributes to p53 accumulation by repressing MDM2. 
Thus, MEG3 cooperates in a pro-apoptotic and anti-proliferation manner. For review 
please see [49]. 
Looking back to hallmark of cancer, we can find several examples of lncRNAs that 
participate in specific aspects of cancer properties: a) sustaining proliferative signaling 
(e.g. SRA, PCAT-1, RN7SK, ncRNAs derived from cell cycle gene promoters, KRASP1 and 
PR antisense); b) evading growth suppressors (e.g. PSF-interacting RNA, ANRIL, GAS5, 
lincRNA-p21 and E2F4 antisense); c) enabling replicative immortality (e.g. TERC and 
TERRA); d) activating invasion and metastasis (e.g. MALAT1, HOTAIR, HULC and BC200); 
e) inducing angiogenesis (e.g. αHIF, sONE/NOS3AS, tie-1AS and ncR-uPAR); and f) 
resisting cell death (e.g. PCGEM1,CUDR, uc.73A(P), SPRY4-IT1, PANDA, LUST and PINC); 
for review please see [50].  
1.3 Metastasis Associated Lung Adenocarcinoma Transcript 1 (MALAT1) 
It is not exaggerated to call MALAT1 as a ‘celebrity in the non-coding RNA world’ as one 
of the most studied lncRNAs so far. MALAT1 has been first demonstrated to play a role 
in cancer metastasis in non-small cell lung cancer from where MALAT1 name is rooted. 
MALAT1 elevated level illustrated a positive correlation with non-small cell lung cancer 
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metastasis. Since then, oncogenic involvement of MALAT1 has been demonstrated in a 
variety of tumors such as bladder, breast, cervix, colon, prostate, stomach, liver and 
osteosarcoma [51, 52]. 
1.3.1 MALAT1 Structure and Localization  
MALAT1 is a long intergenic non-coding RNA (lincRNA) with ~8kb length and is located 
on Chromosome 11q13 in human.  MALAT1 is highly conserved through mammalian 
species [53]. MALAT1 is a very abundant transcript (~3000 copies/cell) and is expressed 
ubiquitously in different tissues. The highest expression of MALAT1 has been reported in 
pancreas and lung [54]. MALAT1 lack the canonical poly (A) tail structure but its primary 
transcript contains a built-in poly (A), which undergoes RNase P and RNase Z cleavage to 
produce 6.7 kb mature product [55, 56]. In general, the processed mature MALAT1 
transcript is very stable, particularly in cancer cells with the half-life observed between 7 
to 18 hours in different cells [57, 58].  MALAT1 is mainly nuclear-retained and is 
accumulated in nuclear speckles with the help of two nuclear speckle localization motifs 
[59]. Nuclear speckle is a nuclear structure/domain that are speculated to play vital role 
in coordinating post-transcriptional RNA processing such as pre-mRNA splicing and 
mRNA export [53, 59-62]. 
1.3.2 MALAT1 Function 
MALAT1 is reported to regulate pre-mRNA processing by interacting with splicing factors 
from SRSF family; SRSF1, SRSF2, SRSF3.  MALAT1 is able to modulate SRSF proteins 
phosphorylation and localization; thereby controls alternative splicing. MALAT1-
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depletion alters the splicing pattern of several pre-mRNAs in HeLa cells [59]. However, in 
vivo experiments in mice do not report any significant change in the alternative splicing, 
and not even in nuclear speckle composition [63-65]. There is a possibility of context-
specific role of MALAT1 in regulation of alternative splicing or nuclear speckle structure 
under particular physiological condition such as stress but not in normal status.  
In addition to alternative splicing, MALAT1 regulates transcription.  For instance, 
MALAT1 is known to interact with unmethylated polycomb 2 protein (PC2) and 
triggering gene expression upon serum stimulation [66]. Two independent studies also 
reported that MALAT1 binds to active transcription loci in cell preferably at those gene 
loci where the transcript go through alternative splicing [67, 68]. Furthermore, MALAT1 
is shown to modulate the function of miRNA by acting as a sponge for miRNAs, including 
miR-9, miR-200 and miR-133, for review please see [69]. In cellular level, the 
involvement of MALAT1 in transcription and post-transcriptional pre-mRNA processing 
enable it to influence the expression of several cell-cycle- and metastasis-associated 
genes [62].  
1.3.3 MALAT1 Regulation 
The expression of MALAT1 in a cell is controlled both at transcriptional and post-
transcriptional level [52]. For example, histone H3K9 (histone 3 lysine 9) demethylase, 
JMJD1A demethylates H3K9 at the MALAT1 promoter, resulting in the induction of 
MALAT1 expression [70]. We have recently demonstrated that a natural antisense 
lncRNA from MALAT1 locus that we named as TALAM1 positively regulates the stability 
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of MALAT1 RNA [71].  In addition, several miRNAs negatively regulate MALAT1 by 
facilitating its degradation [52]. For example, a very recent study has reported mutual 
negative correlation between MALAT1 and miR-1 in TNBC model [72]. This study 
revealed that in BC cells MALAT1 facilitated the expression of Slug, a pro-EMT gene, by 
negatively regulating the interaction of miR-1 and slug mRNA.  The complex regulatory 
layers governing cellular levels of MALAT1 further implicate its dose-dependent and 
context-specific function.  
1.4 Programmed Cell Death 4 - Antisense RNA 1 (PDCD4-AS1) 
PDCD4-AS1 is a two-exon containing transcript locating on chromosome 10q24. PDCD4-
AS1 lacks protein-coding potential but it has been transcribed in the opposite direction 
to a protein-coding gene called PDCD4 (Programmed Cell Death 4). Unlike PDCD4-AS1, 
which has not been studied so far to our knowledge, its protein-coding partner, PDCD4 
is very well established tumor suppressor gene.  
1.4.1 Programmed Cell Death 4 (PDCD4) 
Apoptosis, or programmed cell death, is a vital biological process, which takes place 
during various contexts from development to tissue turnover [73]. Apoptosis and 
eliminating the abnormal cells with aberrant gene expression is one of cell’s defense 
strategies against tumor development [74]. Any malfunction in apoptosis can potentially 
cause diseases such as cancer, and resisting apoptosis is one of the main hallmarks of 
cancerous cells [16]. Therefore, the expression of apoptosis-associated genes is tightly 
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regulated. One of the apoptosis-associated genes is PDCD4 (programmed cell death 4), 
which is up-regulated after initiation of apoptosis. 
1.4.1.1 PDCD4 Structure and Localization 
In human, PDCD4 is located on chromosome 10 and contains two major isoforms, with 
the longest one encoding for a 469 amino-acid protein. PDCD4 is homologous to EIF4G 
(eukaryotic translation initiation factor 4G) and comprises two MA3 domains [75]. MA3 
domains are responsible for protein-protein interactions between EIF4G (eukaryotic 
translation initiation factor 4G) and EIF4A. EIF4A is an ATP-dependent RNA helicase and 
is involved in unwinding RNA structure for translation initiation [76]. EIF4A helicase 
activity requires EIF4G binding. PDCD4 acts as a translational inhibitor, since PDCD4 
binds to EIF4A by its MA3 domains. This PDCD4-EIF4A interaction inhibits the binding of 
EIF4G to EIF4A, and consequently abolishes EIF4A helicase activity [77]. In addition to 
MA3 domains, PDCD4 has been demonstrated to have two nuclear localization signals, 
allowing it to shuttle between nucleus and cytoplasm. PDCD4 is mainly localized in 
nucleus under normal conditions, but is transported to cytoplasm upon specific signals 
such as serum starvation. PDCD4 also contains RNA binding motif at its N-terminal, 
enabling it to bind directly to RNA transcripts [78]. 
1.4.1.2 PDCD4 Function 
PDCD4 tumor suppressor function has been reported to impact the protein expression 
in various types of cancers like breast cancer [79]. As explained above, PDCD4 plays a 
prominent role in EIF4A1-mediated translational inhibition of mRNAs containing 
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structured 5’UTR (e.g. 5’UTR with G-quadruplexes) or mRNAs with 3’UTR containing 
miRNA binding sites [79]. In addition, PDCD4 is an RNA-binding protein and is known to 
interact directly to the coding region of some mRNAs like c-myb and inhibit their 
translation [80].  
PDCD4 influences multiple pathways and its down-regulation induces cell proliferation, 
migration, and invasion in tumor cells. PDCD4 inhibits the expression of MAP4K1, which 
is a kinase upstream of JNK in MAPK pathway. Therefore, PDCD4 indirectly inhibits c-Jun 
phosphorylation and AP1-dependent transcription [81]. Also, PDCD4 inhibits 
undesirable cell proliferation by inhibiting Akt, NF-kB and Cyclin D1 [82]. In addition, 
PDCD4 controls cell proliferation by inducing p21 and Rb binding to E2F-DF and by 
repressing CDK1/cdc2 [83]. Furthermore, PDCD4 reduces the active b-catenin 
accumulation in nucleus, thereby inhibiting b-catenin-dependent transcription, thus 
even further reducing cell proliferation. PDCD4 also increases the expression of E-
Cadherin, while PDCD4-depletion reduces the E-Cadherin level and favors EMT 
(epithelial-to-mesenchymal transition). Hence, PDCD4-depletion induces invasion and 
migration in cancer cells by elevating Snail, reducing E-Cadherin and enhancing EMT 
[84].  
The effect of PDCD4 deregulation on tumor progression has been studied both in vitro 
and in vivo conditions, using in cell lines, and in mice models. For example, in breast 
cancer cell line MCF7, the eIF4A1-dependent translatome was identified by polysome 
profiling. Interestingly, different classes of oncogenic genes were enriched in potential 
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PDCD4 translatome targets, such as oncogenic genes like G-protein family members, 
cyclins and protein kinases [79].  
1.4.1.3 PDCD4 Regulation 
PDCD4 is ubiquitously expressed in all tissues with the highest level observed in liver 
[85]. PDCD4 RNA and protein level is induced by stimuli such as serum deprivation or 
pro-apoptotic drugs like ionomycin and dexamethasone, but not UV irradiation [86]. 
PDCD4 mRNA and protein level is regulated positively and negatively at multiple layers: 
a) translation (e.g. miRNAs like  miR21 which inhibits PDCD4 translation) [87]; b) post-
translational modification (e.g. phosphorylation by Akt and S6K1 and subsequent 
proteasomal degradation of PDCD4) [88]; c) transcription (e.g. v-myb transcription 
factor induces PDCD4 expression) [89]; d) DNA methylation (e.g. DNMT1, demethylates 
DNA and induces PDCD4 expression and CpG island methylation decreased the 
expression of PDCD4) [90]; and e) mRNA stability (e.g. RNA-binding proteins HUR and 
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CHAPTER 2. FUNCTIONAL AND PROGNOSTIC SIGNIFICANCE OF LONG NON-CODING RNA 




Breast cancer is the leading cause of cancer death in women worldwide [92]. Like many 
epithelial tumors, breast cancer (BC) is also a heterogeneous disease with multiple 
subtypes having been elucidated that are substantially different with regard to their 
clinical phenotypes and therapeutic response profiles. The most commonly employed 
clinical subtyping system is based on the presence or absence of three receptors: 
estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor 
receptor 2 (HER2). Based on this, breast cancers are classified into main categories: 
luminal A (ER positive and/or PR positive and HER2 negative), luminal B (ER positive 
and/or PR positive and HER2 negative or positive), HER2+ (ER and PR negative, HER2 
positive) and triple negative (ER/PR/HER2 negative). Triple-negative breast cancers 
(TNBC) are also heterogeneous, further sub-classified primarily into basal-like and 
claudin-low molecular subtypes based on gene expression profiling studies [12, 93-97]. 
Unfortunately, TNBC is associated with poor prognosis and lacks effective targeted 
therapeutic options like Tamoxifen (Nolvadex) or Trastuzumab (Herceptin) that 
have been quite successful in treating luminal A/B or HER2+ cancers, respectively [27, 
98]. There is thus an urgent need to develop prognostic markers that can better stratify 
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TNBC patients with regard to their risk of disease recurrence, as well as therapeutic 
targets that are specifically tailored to TNBC. A better understanding of the biology of 
TNBC thus holds promise in our quest for superior therapeutic treatment options for 
patients diagnosed with TNBC.  
Research efforts to elucidate the biology of breast cancer have thus far been focused on 
the functional characterization of protein-coding genes. Less than 2% of the human 
genome encodes for protein whereas up to 80% of the genome is transcribed into RNA 
[28-30]. Thus, the genome contains a huge repertoire of non-coding RNAs (ncRNAs) [28-
30, 99-101]. NcRNAs come in different sizes from microRNAs of ~20-22 nucleotides (nts) 
to long non-coding RNAs (lncRNAs) of ~200 to thousands nts in length. Among the 
ncRNA categories, we know the least about the function of lncRNAs [102, 103]. 
However, a number of recent studies indicate the involvement of lncRNAs in cancer 
progression, including in breast cancer [104-114]. For example, HOTAIR lncRNA is 
overexpressed in breast cancer patients and represses the expression of metastasis 
suppressor genes, thereby promoting metastasis [107]. Another example includes GAS5 
lncRNA, a cell cycle regulator, which is downregulated in breast cancer samples [115]. 
Some of the candidate lncRNAs that are shown to be aberrantly expressed in breast 
cancer include H19 [112, 116], aHIF [117], BCYRN1 [118], UCA1 [119], SRA RNA [120], 
ZFAS1 [121], CCAT2 [122], LSINCT5 [123], NKILA [111], treRNA [106], Eleanors [124] and 
MALAT1 [72, 125-127]. Recent bioinformatics studies have identified several novel 
lncRNAs, the expression of which is altered in breast cancer patients: some of these 
have the potential to be used as prognostic markers [128-130]. Besides this, lncRNAs 
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also play vital roles in mammary gland development [131, 132]. These reports indicate 
that lncRNAs could be influencing vital processes that are required for mammary cell 
development, and their aberrant expression could contribute to breast tumor growth 
and metastasis.  
MALAT1 is a long (~8kb), highly conserved nuclear-enriched lncRNA, which is abundantly 
and ubiquitously expressed in different tissues [133]. In the nucleus, MALAT1 is 
preferentially enriched in nuclear speckles, which is a non-membranous nuclear 
structure that is known to regulate key post-transcriptional RNA processing, including 
pre-mRNA splicing and mRNA export [53, 59, 60, 62].  Previous studies reveal that 
MALAT1 modulates alternative splicing of pre-mRNA by regulating the activity of several 
of the pre-mRNA processing factors, including SR-family of splicing factors [59, 62]. In 
addition, MALAT1 is involved in transcriptional regulation [54, 66]. This is consistent 
with two recent reports where MALAT1 interacts with actively transcribed gene loci, and 
preferentially interacts with genes, the transcripts of which undergo alternative pre-
mRNA splicing [67, 68]. At the cellular level, MALAT1 regulates cell proliferation by 
controlling the transcription and pre-mRNA processing of key cell cycle-regulated genes 
[62]. Involvement of MALAT1 in cancer metastasis was first reported in the case of non-
small cell lung cancer patients, where overexpression of MALAT1 was positively 
correlated with lung cancer metastasis [53]. Clinically significant upregulation of 
MALAT1 is observed in several other tumors, including those of the lung, bladder, 
breast, cervix, colon, prostate, stomach and liver as well as in osteosarcoma [51, 52].  
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As mentioned earlier, breast cancer (BC) is a heterogeneous disease and is categorized 
into several subtypes. It is reasonable to believe that the MALAT1 interacting protein 
partners and its target genes, the activities of which are regulated by MALAT1, are 
potentially unique for each of the BC subtypes.  It is also not clear whether MALAT1 has 
the potential to drive tumorigenicity in various subtypes of breast cancer. It has recently 
been reported that treatment of ER-negative basal-like breast cancer cell lines with high 
concentration of 17b-Estradiol (E2) decreased the cellular levels of MALAT1, with a 
concomitant decrease in cell proliferation, migration and invasion [127]. These results 
suggest a positive correlation between the low levels of MALAT1 and reduced invasion 
and migration in basal-like BC cells. In the present manuscript we investigated the 
potential involvement of MALAT1 in inducing tumor progression in different subtypes of 
breast cancers.  
Based on data obtained from various BC cell lines and patient samples, we observed 
elevated levels of MALAT1 in luminal subtype of breast cancers. However, our functional 
analyses in different BC cell lines illustrate that the role of MALAT1 in tumor progression 
is not limited to luminal subtype; rather MALAT1 is also actively involved in the tumor 
progression in other BC subtypes, including TNBC cells. Furthermore, the disease-
specific survival data in patients indicated that MALAT1 level could be used as a 
potential prognostic marker in the case of TNBC and HER2+, but not luminal patients. 
More accurately, MALAT1 level in TNBC and HER2+ subtypes could be quantified to 
predict tumor recurrence and metastasis in lymph-node negative (LN-) patients. Thus, 
our results support the potential use of monitoring MALAT1 level as a prognostic 
20 
 
predictor of tumor recurrence and metastasis in patients diagnosed with ER negative 
lymph node negative BC. This would potentially help reduce the occurrence of both 
under-treatment of those hitherto mistakenly assigned to have a low disease recurrence 
risk, as well as over-treatment of those mistakenly assigned to have an elevated disease 
recurrence risk.  
2.2 Results 
2.2.1 MALAT1 levels are altered in breast cancer subtypes.  
To investigate the contribution of MALAT1 in cancer progression in different breast 
cancer (BC) subtypes, we determined MALAT1 levels in various BC subtype samples 
using the Cancer Genome Atlas (TCGA) microarray data set, containing 492 BC patient 
samples of various subtypes [93]. Among different subtypes, MALAT1 showed the 
highest levels in luminal patients while the lowest levels are observed in ER negative 
patient samples of the HER2 or basal-like/TNBC molecular subtypes (Figure 2.1A). 
Further, by performing RT-qPCR, utilizing RNA from a small independent cohort of 
patient samples from Carle Cancer Center, we confirmed the TCGA microarray data, 
demonstrating elevated levels of MALAT1 in patient samples of luminal subtype 
compared to HER2+ and TNBC subtypes (Figure 2.1B).  
A better understanding of MALAT1 function in different subtypes could be obtained by 
manipulating the levels of MALAT1 in breast cancer cell lines of various subtypes. We 
examined the levels of MALAT1 in a human non-tumorigenic breast epithelial cell line 
(MCF10A) and BC cell lines from different subtypes (TNBC subtype: MDA-MB-231, 
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Hs578T, HCC1806; HER2+ subtype: SKBR3; luminal subtype: MCF7, T-47D) (Figure 2.1C). 
RT-qPCR results revealed elevated levels of MALAT1 in T-47D cells, which is of luminal B 
subtype cells. In general, compared to other subtypes of BC cells, TNBC cells contain 
lower levels of MALAT1. In order to study the function of MALAT1 in an isogenic cell line 
background, we expanded our screening to a well characterized and widely reported 
isogenic breast cancer progression cell line series, including four cell lines named M1, 
M2, M3, and M4 [134-138]. These four cell lines are of basal-like/TNBC subtype (basal-
like) and are all derived from non-tumorigenic MCF10A mammary epithelial cells: 
benign MCF10A (M1), transformed H-Ras-transfected MCF10A; MCF10AT (M2), 
tumorigenic but low metastatic MCF10CA1h (M3), and highly tumorigenic/metastatic 
MCF10CA1a.cl1 (M4) [134-138]. In particular, M2 cells were isolated from tumors in 
nude mice that were injected with H-Ras overexpressing M1 cells, whereas both M3 and 
M4 cells were isolated from tumors, which were developed in mouse xenografts after 
the nude mice were injected with M2 cells. Thus, M1-M4 system includes a cancer 
progression spectrum from a relatively normal breast epithelial cell line (M1) to a highly 
tumorigenic and metastatic breast cancer cell line (MCF10CA1a.cl1 or M4). In this 
model, we observed elevated levels of MALAT1 in the highly metastatic M4 cell line 
compared to the other three cell lines (M1, M2 and M3), supporting the potential 
involvement of MALAT1 in driving metastasis in basal-like TNBC cells (Figure 2.1D).  
2.2.2 Role of MALAT1 in tumor progression is not limited to luminal subtype.  
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Next, we investigated the role of MALAT1 in tumor progression by depleting MALAT1 in 
BC cell lines of various subtypes and assayed the effect on various cancer cell attributes; 
proliferation, anchorage-dependent growth by clonogenic (plastic colony formation) and 
anchorage-independent soft agar colony assays. Since MALAT1 shows its highest 
expression in luminal patients/cells, we first depleted MALAT1 using modified antisense 
oligonucleotides (ASOs) in luminal cell lines; T47D and MCF7 cells (Figure 2.2A-B, 
Supplementary Figure2.1A), and tested the effect on long-term anchorage-dependent 
colony formation in plastic plates. Luminal cells upon depletion of MALAT1 showed 
reduction in cell proliferation (Figure 2.2A-B). Our observations are in agreement with 
the recent data, showing the involvement of MALAT1 in tumor progression in luminal 
cells [139]. Next, we performed similar experiments in TNBC cell lines, including MDA-
MB-231 (MB-231) and M4 (MCF10CA1a.cl1) cells. MALAT1 depletion in TNBC cells using 
two independent ASOs (AS-1 & AS-2) against MALAT1 resulted in dramatic decrease in 
cell proliferation (Figure 2.2A-C, Supplementary Figure2.1A). Similar results were also 
obtained in MDA-MB-231 cells when cells were depleted of MALAT1 using independent 
siRNAs instead of DNA-based ASOs (Supplementary Figure2.2). Next, we tested the 
involvement of MALAT1 in the tumorigenicity in BC cells by performing anchorage-
independent soft agar colony formation assay. We consistently observed decreased 
ability for MALAT1-depleted cells to grow in soft agar-coated plates, both for luminal 
and TNBC subtypes, indicating that MALAT1 plays crucial roles in the tumorigenic 
properties of the BC cells (Figures 2.2D, 2.2E).  These results indicate that MALAT1 plays 
vital roles in the tumor progression in various subtypes of BC.  
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2.2.3 MALAT1 regulates metastasis in TNBC cells.  
Luminal cells such as MCF7 and T-47D generally display weak metastatic properties 
under in vitro and in vivo conditions. Therefore, to investigate the involvement of 
MALAT1 in metastasis, we performed in vitro metastatic assays in control and MALAT1-
depleted TNBC cell lines (MDA-MB-231 and M4), both of which are previously shown to 
be highly metastatic in nature [140].  We evaluated both migratory and invasive 
properties of control and MALAT1-depleted cells using migration and invasion transwell 
chamber assays in vitro. MALAT1 depletion resulted in decrease in the migratory (Figure 
2.3A-B) and invasive (Figure 2.3C-D) properties of both these cell lines. Similar results 
were observed using another independent set of ASO as well as siRNAs, against MALAT1 
(Supplementary Figure2.3). 
Next, we examined whether the overexpression of MALAT1 could induce proliferation, 
tumorigenicity and metastasis in BC cell lines. To test this, we stably expressed wild type 
mouse Malat1 cDNA in non-tumorigenic MCF10A cells using retro- or lenti-viral 
mediated transduction (Supplementary Figure2.4A). MCF10A cells form three-
dimensional acini when grown in 3D culture in Matrigel-a basement membrane-like 
extracellular matrix [141]. Such organotypic three dimensional MCF10A cell cultures 
mimic several vital aspects of mammary gland morphogenesis and architecture, and is 
routinely used to study mammary gland biology in vitro [141-144]. We grew control and 
MALAT1-overexpressing MCF10A cells under 3D-conditions and analyzed their growth. 
MALAT1-overexpressing MCF10A cells showed increased proliferation compared to 
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control cells, as observed by increased size in acini structure (Supplementary Figure2.4B) 
as well as by enhanced labeling by Ki67 antibody (Supplementary Figure2.4C).  
Next, we analyzed the involvement of MALAT1 in the metastatic properties of cells. In 
our hands, MALAT1 overexpression in luminal cell line, MCF7 showed no effect on 
migration and invasion (Figure 2.4A-2.4D, Supplementary Figure2.1B). At the same 
instance, MALAT1-overexpressed weakly tumorigenic M2 cells showed increased 
migration (Figure 2.4A-B) and invasion (Figure 2.4C-D). This result suggests that under in 
vitro conditions, MALAT1 level may be more critical in regulating metastasis in TNBC 
cells compared to luminal subtype.  
We also determined proliferation and tumorigenic properties of MDA-MB-435s cell line 
upon MALAT1 overexpression. The exact origin of MDA-MB-435s cells is under constant 
debate [145]. MDA-MB-435s was initially thought to be of breast cancer origin [146], 
and is still extensively used in breast cancer research [147-155]. For example, global 
gene expression analyses indicate that MDA-MB-435s cells show similar gene signature 
to that TNBC/basal-like BC subtype [156]. However, other independent studies indicate 
that MDA-MB-435s cells could be originally derived from melanoma cells [157-159]. In 
general, MALAT1-overexpressed MDA-MB-435s cells showed increased proliferation 
under normal as well as under serum-starved conditions (Supplementary Figure2.5A-B). 
In addition, MALAT1-overexpressed cells also showed increased number of colonies in 
anchorage-independent soft agar assay (Supplementary Figure2.5C). Furthermore, 
MALAT1-overexpressed cells showed decreased sensitivity to anisomycin-induced 
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apoptosis (Supplementary Figure2.5D), condition that is similar to what is observed in 
the case of oncogene-activated cells [160]. Experiments utilizing serum starvation and 
anisomycin –induced apopotosis provide insights into the oncogenic potential of 
MALAT1 in the context of apoptosis of the breast cancer cells. For example, malignant 
cancer cells are known to be more resistant to apoptosis, thus reduced apoptosis after 
exposure to anisomycin in reduced serum condition points towards the oncogenic 
potential and anti-apoptotic properties of MALAT1. All these results indicate that 
irrespective of the cell of origin, MALAT1 enhances the tumorigenic properties of MDA-
MB435s cells.  
To investigate the oncogenic and metastatic potential of MALAT1 in vivo, we injected 
MDA-MB-435s cells with GFP reporter, over-expressing MALAT1 or the empty vector 
subcutaneously into NOD-SCID mice. We found that MALAT1 overexpression further 
induces the oncogenic property of MDA-MB-435s cells as they formed large tumors in 
mice (Figure 2.4E). This result suggests that MALAT1 was capable of imparting greater 
oncogenic potential in MDA-MB-435s cells. To examine the metastatic potential of 
MALAT1, we looked at the metastatic effect of MALAT1 overexpression in lungs of mice 
injected with GFP +ve MDA-MB-435s cells overexpressing full length human MALAT1 or 
the empty vector. We found that over-expression of MALAT1 significantly increased the 
metastasis capacity of MDA-MB-435s cells (Figure 2.4F). Altogether, these results 
confirm that under in vivo conditions, over expression of MALAT1 enhances the 
tumorigenic and metastatic properties of cancer cells. 
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We have previously demonstrated the involvement of MALAT1 in regulating the 
localization and activity of several pre-mRNA splicing factors, including the SR family of 
splicing factors such as SRSF1 [59, 161]. For example, MALAT1-depleted human cells 
showed changes in the alternative splicing of pre-mRNAs of several genes that are 
involved in tumor progression and metastasis [54, 62, 139, 161]. We therefore 
determined whether overexpression of MALAT1 influences the alternative splicing of 
key cancer-associated genes in MD-MBA-435s cells. Particularly, we looked at the 
changes in the SRSF1-mediated alternative splicing in these cells. RT-PCR-based splicing 
assays revealed that MALAT1-overexpressed cells showed changes in the SRSF-mediated 
alternative splicing of pre-mRNAs of several cancer–associated genes, including TEAD, 
BIN and BIM (Supplementary Figure2.5E). These results indicate that even in breast 
cancer cells differential levels of MALAT1 could alter alternative splicing of key 
oncogenic gene mRNAs, preferentially through modulating the activity of SR-splicing 
factors, such as SRSF1. 
2.2.4 MALAT1 regulates the expression of genes involved in cell cycle progression and 
epithelial-to-mesenchymal transition in BC cells.  
Next, we attempted to identify the downstream target genes of MALAT1, the altered 
expression of which in MALAT1-expression altered cells, contributes to changes in cell 
proliferation, tumor progression and metastasis. We had previously reported that the 
levels of MALAT1 are regulated during the cell cycle, and MALAT1 modulates the 
expression of a large number of cell cycle-regulated genes in human lung fibroblasts 
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[62]. To determine if MALAT1 regulates the expression of similar set of cell cycle genes 
in breast cancer cells as well, we performed RT-qPCR to quantify the mRNA levels of 
several of these genes in control and MALAT1-depleted M4 cells (Figure 2.5A). MALAT1-
depleted M4 cells showed downregulation of several of the candidate cell cycle genes, 
several of which are known to play vital roles in G1/S and mitotic progression. Next, we 
determined whether MALAT1 overexpression in non-tumorigenic M2 cells would induce 
the expression of these cell cycle genes. We consistently observed upregulation of a few 
(CENPE and TUBA1A) but not all of the cell cycle-regulated genes in MALAT1 
overexpressed M2 cells (Supplementary Figure2.6A). Several of the other candidate 
mRNAs showed only moderate increase in their levels upon MALAT1 overexpression. 
To determine changes in the expression of genes involved in metastasis in MALAT1-
depleted BC cells, we used an EMT (Epithelial-mesenchymal transition) profiler qPCR 
array (Qiagen). EMT is a process in which epithelial cells lose epithelial cell-cell 
adhesions, gain mesenchymal properties and become increasingly migratory and 
invasive in nature [162]. Under physiological conditions, EMT happens during mesoderm 
and neural tube formation during embryonic development [163]. EMT is also observed 
during organ fibrosis and wound healing where cells lose adhesion properties and 
migrate to repair the wound [164]. Under pathological circumstances, EMT is involved in 
the initiation of cancer metastasis where tumor cells depart the primary tumor site and 
invade and migrate to other tissues, thereby expanding their territories [165].  EMT 
profiler assay in control and MALAT1-depleted M4 cells revealed that the expression of 
a significant number of EMT genes was affected upon MALAT1 depletion; Table S1 in 
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[166]. Some of the key downregulated genes in MALAT1-depleted samples include 
SPARC, SNAI2, MMP2, TGFB2, WNT5B, VIM, FDZ7, WNT11 and WNT5A. These genes are 
known to be upregulated during EMT. We further quantified the mRNA levels of several 
of these genes in control and MALAT1-depleted M4 cells by RT-qPCR, and observed 
consistent results (Figure 2.5B). Furthermore, we examined the level of a panel of these 
mRNAs upon MALAT1 depletion in both M4 and MDA-MB-231 cells using two 
independent ASOs (AS-1 and AS-2) and observed similar results (Supplementary 
Figure2.7A-B).  We also determined the mRNA levels of the EMT genes in MALAT1-
overexpressed M2 cell line. We consistently observed increased expression of genes 
such as VIM and WNT5A in MALAT1-overexpressed cells (Supplementary Figure2.6B). 
The expression of genes such as IL1RN, CDH1, RON, FGFBP1, DSP, OCLN, CAV2, NUDT13, 
PPPDE2 and RGS2 are known to be downregulated during EMT. Consistently, MALAT1-
depleted M4 cells showed increased mRNA levels of these genes (Supplementary 
Figure2.8). Deregulation of several EMT genes upon altered expression of MALAT1 in 
metastatic BC cells suggests that MALAT1 could regulate metastasis through regulating 
the expression of key EMT genes. 
2.2.5 Elevated MALAT1 levels correlate with poor prognosis in LN- patients of TNBC 
and HER2+ subtypes.   
We next sought to examine whether the above delineated role of MALAT1 in regulating 
aggressive cellular traits and mediating tumor progression and metastasis has a 
measurable prognostic impact in human breast cancer patients. When patients 
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diagnosed with all BC molecular subtypes (Luminal A/B, HER2 and basal-like/TNBC) were 
analyzed together, there were no statistically significant differences in Disease-Specific 
Survival (DSS) between patients whose tumors displayed high or low MALAT1 
expression, irrespective of the specific percentile cutoff value employed (data not 
shown). When DSS was analyzed in this cohort within each subtype (Luminal A/B, HER2 
and basal-like/TNBC), MALAT1 expression level still was not associated with any 
statistically significant difference with respect to DSS, irrespective of the specific 
percentile cutoff value employed (Figure 2.6A-D). Only when we examined the LN 
negative subset of patients within each molecular subtype did significant differences in 
DSS become apparent between low and high MALAT1 expression groups. This is of great 
clinical significance as disease recurrence and metastasis in patients diagnosed with 
cancers of ductal origin (e.g. adenocarcinomas), in the absence of lymph node 
involvement, is strongly suggestive of the less common hematogenous route of 
dissemination that is more commonly encountered in the case of tumors of 
mesenchymal origin (e.g. sarcomas). In univariate analysis, DSS was significantly worse 
in tumors from patients diagnosed with ER negative lymph node negative breast cancer 
which displayed the top quartile of subtype-specific MALAT1 expression (HR= 2.32, 
95%CI 1.02-5.31, P = 0.047 in HER2+ LN-, HR=2.46, 95%CI 1.27-4.78, P = 0.008 in basal-
like LN-, respectively) (Figure 2.6G-H). This pattern was not observed in the case of 
Luminal A LN- or Luminal B LN- patients thereby suggesting a molecular subtype context 
specific effect of MALAT1 on mediating tumor progression and metastasis (Figure 2.6.E-
F).  Surprisingly, such a correlation was not observed in the case of LN+ patients (data 
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not shown). Furthermore, multivariable analysis confirmed MALAT1 to have 
independent prognostic significance in the basal-like lymph node negative patient 
subset (HR=2.64, 95%CI 1.35-5.16, p=0.005). While similar multivariable analysis in the 
HER2+ LN- group (HR=2.28, 95%CI 1.00-5.22, p=0.052) did not emerge to statistical 
significance to confirm the prognostic importance of MALAT1 expression in this 
subgroup of patients (that had been noted on the initial univariate analysis), this effect 
is likely secondary to limitations of the sample size and merits investigation in a larger 
breast cancer patient cohort. 
2.2.6 MALAT1 shows subtype-specific correlation with EMT genes in breast cancer 
patients.   
Based on the data obtained from BC cell lines and BC patients, MALAT1 facilitates tumor 
progression differently in various BC subtypes. We therefore hypothesize that the 
subtype-specific function of MALAT1 could potentially be due to the role of MALAT1 in 
regulating the expression of specific subset of genes in each of the subtype. To find 
potential target/s, we explored the expression correlation between MALAT1 and co-
expressed genes in patients using data from the Curtis et al. clinical dataset [167]. To 
identify potential partners/targets, we first curated the literature to derive a list of 
several EMT-associated genes and other transcription factor genes (250 genes ~ 459 
hits) with potential roles in tumor development and metastasis. We then calculated 
Pearson Correlation Coefficient (PCC) as a measure for correlation between the 
expression of MALAT1 and the gene of interest; Table S2 [166]. Then, we calculated the 
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p-value and confidence level for each correlation. We identified genes whose mRNA 
levels are positively and negatively correlated with MALAT1 (Figure 2.7A; p-value<0.05). 
The detailed gene list is documented in Table S2 [166]. Our analyses identified several 
patterns of correlation between MALAT1 and specific set of genes.  The expression of 
few genes was correlated with MALAT1 in patient samples from all of the subtypes 
(Figure 2.7B-C]. For example, TBX1 levels were correlated significantly with MALAT1 
levels in all of the tested samples (Figure 2.7B). TBX1 gene encodes for a T-box 
transcription factor 1, and its elevated level is associated with breast tumor 
development [168]. TBX2 is another member of this family, which showed negative 
correlation with MALAT1. Genes such as GREM1 and FOXC2 displayed opposite 
correlation trend in normal and patient samples regardless of the subtype tested (Figure 
2.7D-E). Interestingly, for another subset of genes, the correlation with MALAT1 was 
subtype specific. SERPINE1 and ITGB4 are two examples of genes, which showed 
subtype-specific correlation in their levels with MALAT1 (Figure 2.7F-G).  In addition, 
MALAT1 level was also correlated with specific set of genes in each LN- and LN+ pools; 
Table S2 [166] (Figure 2.7H-I; data shown for TNBC and HER2). For example in the case 
of TNBC subtype, genes such as TBX1, KLF3, EPCAM, SLC2A9, TP53 and MME showed 
similar pattern in both LN- and LN+ pools (Figure 2.7J). On the other hand, genes such as 
TBX4, MLPH, RTEL1, RHBDF2, SMPDL3B and TBX3 correlated with MALAT1 differentially 
in LN- and LN+ patients (Figure 2.7K).  These correlation analyses in patient samples 
imply that MALAT1 could potentially regulate the expression of key genes involved in 
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tumor progression and/or metastasis in BC cells of specific subtype or of different LN 
status.  
2.3 Discussion  
MALAT1 is a highly abundant and conserved lncRNA, and is localized to the nuclear 
speckle sub-compartment. Earlier studies indicate that MALAT1 modulates transcription 
and pre-mRNA processing of a large set of genes [54, 59, 62, 66, 139]. MALAT1 is 
deregulated in several tumors, and is potentially of significant clinical importance. In this 
study, we have determined the involvement of MALAT1 in different subtypes of breast 
cancer. Based on the gene expression data in BC tissues and in cell lines, MALAT1 levels 
were consistently high in luminal subtype and relatively low in TNBC subtypes. This 
implies that MALAT1 might play a crucial role in tumor progression in luminal subtype 
over TNBC subtype. However, our functional analysis revealed that though MALAT1 is 
less abundantly expressed in TNBC subtype compared to luminal subtypes, it plays 
crucial role in regulating the expression of key genes that are involved in tumor 
progression and metastasis in TNBC cells.  
The molecular signature of gene expression in TNBC is one of the most unique among all 
of the intrinsic subtypes of breast cancers [93, 97, 169, 170]. In addition, the age of 
disease incidence, and the risk factors associated with TNBC patients are different and 
sometimes opposite when compared to other subtypes of BC [171].  It was hypothesized 
that the various subtypes of breast cancer could be originated from different cell types, 
and some of these differences could be attributed to different cell origins [172]. It is 
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possible that differential levels of MALAT1 in various subtypes of BC could also be 
attributed to various cell types from where the tumor is derived.  
To identify the role of MALAT1 in breast tumor progression, we determined the 
potential changes in the levels of the RNA of interest in a series of BC cell lines of 
isogenic background. The M1-M4 isogenic cell line model provides an ideal tool to 
answer such questions. All of the four cell lines are derived from MCF10A, which is a 
well-established non-tumorigenic mammary epithelial cell line [173]. The properties of 
M1 to M4 cells reflect a natural progression of cancer from a non-tumorigenic (M1), to 
hyper-proliferative, non-tumorigenic (M2), to tumorigenic, non-metastatic (M3), and 
finally to highly tumorigenic and metastatic (M4) state. Further, PAM50 analyses 
indicate that M1-M4 cells show basal-like/TNBC gene signature (data not shown), 
making them an ideal model to study the involvement of a gene in tumor progression 
and metastasis in TNBC subtype. We observed elevated levels of MALAT1 in M4 cells 
compared to M1-M3. Furthermore, MALAT1 depletion in M4 and overexpression in M2 
cells decreased and increased tumorigenic and metastatic properties of these cells, 
respectively. This supports our hypothesis that MALAT1 plays an active role in regulating 
tumor progression and metastasis in TNBC cells.  
To determine whether MALAT1 expression in breast cancer is capable of exerting 
prognostically significant effects, we compared DSS (disease-specific survival) between 
patients grouped according to high or low MALT1 expression. Elevated MALAT1 levels 
were found to be associated with decreased DSS in ER negative, lymph node negative 
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patients of the HER2 and basal-like or TNBC molecular subtypes. Multivariate analysis 
further confirmed the independent prognostic significance of MALAT1 expression in the 
basal-like lymph node negative patient subset. This further confirms our hypothesis that 
the functional effect of MALAT1 on tumor progression and metastasis is context 
dependent upon the molecular subtype and clinical phenotype of the cancer, and not 
merely based upon its expression level alone. We propose that the functional 
significance of MALAT1 as a metastasis driver and its potential use as a prognostic 
marker is most promising for those patients diagnosed with ER negative, lymph node 
negative breast cancer who might otherwise mistakenly be stratified to have low 
recurrence risk. Our findings are of particular clinical significance as MALAT1 levels in 
breast cancer samples could be used to predict future onset of metastatic disease in LN- 
patients who might otherwise be perceived to be at a low risk for metastasis. This 
information could influence treatment recommendations in favor of administering 
adjuvant chemotherapy (with the therapeutic rationale of reducing or curbing the risk of 
such future metastatic events) in this group of patients who might otherwise not be 
offered such therapy. Our results thus support the potential use of monitoring MALAT1 
expression level as a predictor of tumor recurrence and metastasis in patients diagnosed 
with ER negative lymph node negative BC. Subsequent clinical validation studies to 
confirm the prognostic predictive ability of MALAT1 expression, if successful may find 
clinical utility in guiding treatment recommendations to undergo systemic adjuvant 
chemotherapy in a group of BC patients who might otherwise mistakenly be perceived 
to be at low risk of disease recurrence.  
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We observed that TNBC cells that were either overexpressing or depleted of MALAT1 
showed altered expression of genes that are involved in cell cycle, tumor progression 
and EMT. In addition, MALAT1 and mRNA correlation analysis in Curtis patient data sets 
identified several EMT genes the mRNA levels of which were potentially correlated with 
MALAT1 levels in specific breast cancer intrinsic subtypes. Particularly, we observed that 
each BC subtype contains unique set of genes, the mRNA levels of which were 
specifically correlated with MALAT1 levels only in one subtype but not in others. Such 
data support the view that MALAT1 might contribute to regulating different network of 
genes not only in different cancers but also in different subtypes or LN – or LN + types of 
a specific cancer such as breast cancer. A very recent study reported that in luminal B 
breast cancer model system, depletion of MALAT1 did not alter the expression of genes 
involved in EMT, even though the cells showed defects in tumor progression and 
metastasis [139]. On similar lines, several earlier studies have reported that in various 
cancers MALAT1 influences tumor progression and metastasis by controlling distinct 
cellular pathways [51, 52]. For example, MALAT1 is shown to modulate the expression 
of several of the cell motility and metastasis-associated genes at the transcriptional 
and/or post transcriptional level in lung cancer [54, 174]. On the other hand, MALAT1 in 
bladder cancer cells is reported to associate with a polycomb repressive component, 
SUZ12. Consequently, this association influences the differential expression of N-
Cadherin and E-cadherin, thereby facilitating EMT [175]. In cervical cancers, depletion of 
MALAT1 induces the expression of pro-apoptotic genes and inhibits the activity anti-
apoptotic genes [176]. Finally, in colon cancer cells, MALAT1-depletion is reported to 
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decrease the nuclear localization of -catenin thereby inhibiting wnt/-catenin signaling 
[177]. In luminal breast cancer cells, a whole-genome analysis identified several 
mutations in SRSF1-binding region of MALAT1. This may affect the SRSF1-mediated pre-
mRNA splicing in these cells since MALAT1 is known to interact with SRSF1 and regulates 
the activity of SR proteins [59, 62, 125, 161]. A very recent study from the Spector 
laboratory also pointed out the involvement of MALAT1 in regulating the expression and 
pre-mRNA splicing of genes that are involved in differentiation and pro-tumorigenic 
pathways in breast cancer model system [139].  All this data further supports our 
argument that MALAT1-mediated changes in gene expression are cell or tissue type 
specific.  In addition, our correlation analysis has provided vital hints about the potential 
targets and interacting partners of MALAT1 in specific subtypes of BC.  
MALAT1 is a tightly regulated and multifunctional lncRNA, which controls key gene 
networks by fine-tuning both transcription and alternative splicing of specific cancer-
associated genes in different subtypes of breast cancer cells.  Future studies will confirm 
such interactions, and will also decipher the mechanistic significance of such 
interactions between MALAT1 and specific set of genes in causing tumor progression 
and/or metastasis. 
2.4 Methods and Materials 
Cell culture: MDA-MB-231 and MCF7 cells were cultured in DMEM supplemented with 
1mM sodium pyruvate, 100U/mL penicillin, 100 µg/mL streptomycin and 10% fetal 
bovine serum. M4 cells were cultured in DMEM/F12 medium supplemented with 100 
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U/mL penicillin, 100 µg/mL streptomycin and 5% horse serum. M1-M3 cells were 
cultured in DMEM/F12 medium supplemented with 100 U/mL penicillin, 100 µg/mL 
streptomycin, 20ng/mL EGF (epidermal growth factor), 0.5 µg/mL Hydrocortisone, 
100ng/mL Cholera toxin, 10 µg/mL insulin and 5% horse serum. SKBR3 cells were 
cultured in McCoy's 5a Medium supplemented with 100U/mL penicillin, 100 µg/mL 
streptomycin and 10% fetal bovine serum. T-47D cells were cultured in RPMI-1640 
Medium supplemented with 0.2 Units/ml insulin, 100U/mL penicillin, 100 µg/mL 
streptomycin and 10% fetal bovine serum.  
RNA extraction and RT-qPCR analysis: Total cellular RNA was extracted from cells using 
Trizol reagent (Invitrogen) following manufacturer’s protocol. RNA was reverse 
transcribed into cDNA using Random hexamers and Multiscribe reverse transcriptase 
(Applied Biosystems). Quantitative RT-PCR was performed using StepOne Plus system. 
(Applied Biosystems) and primers listed in Table S3.  
MALAT1 Knockdown/overexpression experiments: MALAT1 depletion was carried out by 
transfecting cells either using antisense oligonucleotide (ASO) or siRNAs against MALAT1 
[50]. Briefly, cells were transfected with control or MALAT1-specific ASOs (100 nM final 
con.) or siRNAs (40-50 nM con) for two rounds with a gap of 24 hrs using Lipofectamine 
RNAiMax reagent (Invitrogen, USA). For overexpression, full-length mouse or human 
Malat1/MALAT1 were expressed using retro- or lenti virus-mediated transduction, and 
stable lines were selected using puromycin selection. Empty vector transduced cells 
were used as control. 
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Alternative pre-mRNA splicing assay: Pools of MDA-MB-435s cells were transduced with 
the indicated lentiviruses encoding MALAT1 or an empty vector. After puromycin 
selection, cells were lysed and RNA was isolated. Splicing patterns of SRSF1 target genes 
(BIM, BIN-1 and TEAD-1) were examined using the indicated isoform specific primers. 
GAPDH mRNA was used as control. Primers are listed in Table S3 [166]. 
Total RNA was extracted with Tri-reagent (Sigma) and 1 µg of total RNA was reverse 
transcribed using M-MLV reverse transcriptase (Promega). PCR was performed on1/10 
volume 2µl of the cDNA, in 25 µl reactions containing 12.5 µl of PCR Mix (Kapa 
Biosystem), 1.25 µl of 10 µM forward and Reverse Primer,1.8 µl of DMSO. PCR 
conditions were as follows 950C for 3 minutes, then 34 cycles of 950C for 15 sec, 600C 
for 15 sec, 720C for 45 sec followed by 10 minutes at 720C. PCR products were 
separated on 2% agarose gel.  
Proliferation Assay: Cells were seeded in 96 well plates. After stipulated time, they were 
fixed with 2.5% Glutaraldehyde and stained with 1% methylene blue in 0.1M Borate 
Buffer. The absorbance of the acid extracted stain with 0.1N HCl was measured on a 
plate reader (Bio-rad) at 655nM. 
Anisomycin-mediated cell death assay: MDA-MB-435s cells were transduced with 
lentiviruses encoding an empty vector or full length human MALAT1. Following 
Selection, 0.2 × 106 cells were seeded per well in six well plates. 24 hours later, cells 
were incubated with 1 µM Anisomycin in 0.1% serum DMEM medium for 24 hours. 
Medium and PBS washes were collected together with cells trypsinized from each well 
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into 15ml tubes and centrifuged at 1500RPM for 5 min. Cells were washed with PBS and 
after another centrifugation were resuspended in 50 µl of HEPES Buffer. 10 µl of the cell 
suspension was mixed with 10 µl of 4% trypan blue solution and live/dead cells were 
counted using a Bio-Rad TC-10 Automated Cell Counter. 
Plastic Colony formation assay (anchorage-dependent growth): 1000 cells (control, 
MALAT1-depleted or –overexpressed) per well were seeded in a 6-well plate. After 7-14 
days, cells were washed, fixed with ice-cold methanol and stained with crystal violet 
0.05% in MeOH:H2O with ratio of 1:9. Colony numbers were counted per each well.  
Agar formation assay (Anchorage-independent growth): In a 12-well plate, 2ml medium 
with 0.5% low-melt agarose was laid down and the plate was placed at 40C for 20 
minutes. Next, 2500 cells (control, MALAT1-depleted or –overexpressed) were 
resuspended in 1.5 ml medium with 0.35% low-melt agarose was laid down on the 
bottom layer. The plate was placed at 40C for another 20 min. Then, it was transferred 
to incubator at 370C, 5% CO2 and cultured for 18-30 Days. Cells were stained with 
crystal violet 0.005% in MeOH: H2O: Acetic Acid with ratios of 5:4:1 respectively. 
Migration assay:  Migration assay was carried out using 8µM transwell migration 
chambers (Corning, Cat# 354578). Cells were starved in serum-free medium for 5-6 hrs, 
then trypsinized and resuspended in serum-free medium and seeded in transwell 
chamber. Then, the chamber was placed in a well of a 24-well plate with 750 µL serum-
containing medium per well. Cells were cultured for 16-24 h at 370C, in 5% CO2, fixed 
and were stained with crystal violet 0.05%. 
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Invasion assay: Invasion assay was performed using Matrigel invasion chambers 
(Corning, Cat#354483). Chambers were rehydrated according to manufacturer’s 
protocol. Similar to migration assay, cells were starved for 5-6 hrs, then trypsinized and 
seeded in transwell chambers containing serum-free medium. Chambers were placed in 
a well with serum-containing medium. Cells were cultured for 16-24 h at 370C, in 5% 
CO2, fixed and were stained with crystal violet 0.05%. 
Xenograft Studies: Stable pools of MDA-MB-231 and MDA-MB-435s cells expressing full 
length human MALAT1 or the empty vector were injected (2X106 cells/site in 200µl PBS) 
subcutaneously into each rear flank of NOD-SCID mice (8 weeks old) using a 26 gauge 
needle. Tumor growth was measured bi-weekly. Tumor volume was calculated using the 
formula, Tumor Volume= (Length X Width2)/2. MDA-MB-435s cells are GFP labeled, so 
their metastatic potential can be examined by looking at the expression of GFP in organs 
distant from the site of injection. In the present study, after 6 weeks, the lungs were 
removed and metastases were visualized using GFP expression. 
Animals were sacrificed by a lethal dose of anesthesia. Mice were held in specific 
pathogen free conditions. All animal experiments were performed in accordance with 
the guidelines of the Hebrew University committee for the use of animals for research. 
Survival analysis: Prognostic significance of MALAT1 in predicting Disease Specific 
Survival (DSS) in breast cancer patients was examined in the Curtis et al., microarray 
data set (n=1992) [167]. Univariate and multivariable analyses were performed using 
log-rank test and Cox regression model, respectively using MedCalc (MedCalc Software, 
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Ostend, Belgium). Survival plots were created by using Kaplan-Meier methods using 
GraphPad Prism software (GraphPad Software, La Jolla, CA).   
Correlation analysis: The expression data of 250 cancer-related genes (459 hits including 
hits from EMT-associated genes and transcription factors) were retrieved from Curtis 
clinical dataset [167]. Pearson Correlation Coefficient (PCC) was calculated as a measure 
for estimating the correlation between the expression of MALAT1 and each of the genes 







Figure 2.1  Relative levels of MALAT1 in breast cancer tissue samples and cell lines of different subtypes. 
(A) Box-plot data depicting the relative levels of MALAT1 in breast cancer patient samples from different 
subtypes, obtained from the TCGA microarray data set. TNBC (n=77), HER2+ (n=54), Luminal A (n=232), 
Luminal B (n=129) (B) RT-qPCR analyses to determine the relative levels of MALAT1 in Carle Cancer Center 
patients; TNBC (n=5), HER2+ (n=5), Luminal A (n=3), Luminal B (n=3). Bars indicate the average of three 
biological repeats ±SEM. (C) RT-qPCR analyses to determine the relative levels of MALAT1 in cell lines of 
different breast cancer subtypes, bars indicate the average of three biological repeats ±SEM (D) RT-qPCR 
analyses to determine the relative levels of MALAT1 in M1-M4 cell lines, two-tailed Student t-test was 




Figure 2.2 Depletion of MALAT1 in breast cancer cells decreases cell proliferation and anchorage-
independent colony formation.  (A-B) Depletion of MALAT1 using DNA antisense oligonucleotides 
decreases cell proliferation in different breast cancer subtypes. Cell proliferation is evaluated by 
clonogenic (plastic colony formation) assay (C) Plastic colony formation assay in MDA-MB-231 cells that 
are treated with control or two different MALAT1-specific antisense oligonucleotides. (D-E) MALAT1 
depletion decreases anchorage-independent growth in different cell lines. Data represented in A-E are 




Figure 2.3 MALAT1 depletion decreases migration and invasion in metastatic TNBC cells. (A) 
Representative micrographs showing the migration of cells upon control and MALAT1-depletion. (B) 
Migration assay quantification from three biological repeats and error bar indicates SEM. (C) 
Representative micrographs showing invasion of cells upon control and MALAT1-depletion. (D) Invasion 







Figure 2.4 MALAT1 overexpression accelerates metastasis in TNBC cells. (A) Representative micrographs 
showing the migration of MCF7 and M2 cells upon control and MALAT1-overexpression. (B) Migration 
assay quantification from three biological repeats. Error bar indicates SEM. (C) Representative 
micrographs showing invasion of MCF7 and M2 cells upon control and MALAT1-overexpression.  (D) 
Invasion assay quantification from three biological repeats. Error bar indicates SEM. (E) Pools of GFP-
labeled MDA-MB-231 and MDA-MB-435s cells were transduced with the indicated lenti virus encoding 
MALAT1 or an empty vector. After puromycin selection, cells (2X10
6
) were injected subcutaneously into 
NOD-SCID mice (n=10). Tumor volume was measured bi-weekly. (F) 6 weeks after injection, mice were 
sacrificed and lungs from mice injected with the GFP-labeled MDA-MB-435s cells were visualized to detect 




Figure 2.5  MALAT1 regulates the expression of genes involved in cell cycle progression and EMT 
signature. RT-qPCR analyses to detect relative levels of mRNA of genes that are involved in cell cycle (A) 
and EMT (B) in control and MALAT-depleted M4 cells.  
 
 
Figure 2.6 MALAT1 is a potential prognostic marker in patients diagnosed with ER negative lymph node 
negative breast cancer. Prognostic significance of MALAT1 expression in breast cancer with regard to 
disease-specific survival (DSS) in an independent 1992 patient Microarray Dataset [167]. Kaplan-Meier 
analysis of DSS in patients diagnosed with tumors of Luminal A, Luminal B, HER2 or basal-like/TNBC 
subtypes with a subtype-specific top quartile cutoff (A-D). Kaplan-Meier analysis of DSS in lymph node–
negative (LN-) patients diagnosed with tumors of Luminal A, Luminal B, HER2 or basal-like/TNBC subtypes 




Figure 2.7 Subtype-specific expression correlation of MALAT1 and EMT signature genes in breast cancer 
patients. (A) The EMT signature genes showing potential correlation with p-value<0.05 in different 
subtypes, the gene names not shown due to space limit (for detailed information see Table S2). 
Representative genes showing potential correlation in all subtypes (B) TBX1/ILMN_2248112 (gene 
name/probe number) and (C) TBX2/ILMN_1792256. Representative genes with different pattern in 
normal and patient samples (D) GREM1/ILMN_2124585 and (E) FOXC1/ILMN_1738401.   Representative 
genes showing subtype-specific correlation (F) SERPINE1/ILMN_1744381 and (G) ITGB4/ILMN_2317543. 
The EMT signature genes showing potential correlation with p-value<0.05 in LN- and LN+ pool in (H) TNBC 
and (I) HER2 patients (for detailed information see Table S2). Representative genes showing correlation in 
LN- and LN+ TNBC samples (J) with similar pattern; TBX1/ILMN_2248112, KLF3/ILMN_1670245, EPCAM/ 
ILMN_2160209, SLC2A9/ILMN_1668312, TP53/ILMN_1779356, MME/ILMN_1786319 and (K) with 
different pattern; TBX4/ILMN_1745827, MLPH/ILMN_1795342, RTEL1/ILMN_1709538, 




2.6 Supplemental Figures 
 
Supplementary Figure 2.1  MALAT1 knockdown efficiency upon (A) knockdown using AS1 in BC cell lines, 
Scrambled AS was used as control, (B) knockdown using AS1, AS2 and siMALAT1 in MDA-MB-231 cell line, 
Scrambled AS and siGL3 were used as control. (C) hMALAT1 full length overexpression in MCF7 and M2 




Supplementary Figure 2.2  Clonogenic (Plastic colony formation) assay in control and MALAT1-depleted 





Supplementary Figure 2.3  Reduced levels of (A) Migration and (B) invasion upon knockdown of MALAT1 
using another independent MALAT1-specific ASO (AS-2) in MDA-MB-231 cells. Reduced levels of (C) 







Supplementary Figure 2.4  MALAT1 overexpression induces hyper-proliferation in MCF10A. (A) mMALAT1 
overexpression in MCF10A cells. (B) Acini Structure size in control and MALAT1-overexpressing MCF10A. 




Supplementary Figure 2.5  MALAT1 increases the oncogenic potential of MDA-MB-435s cells (A) MDA-
MB-435s cells were transduced with lenti viruses encoding an empty vector or full length human MALAT1. 
These cells were seeded on 96 well plates and proliferation was measured as described in materials and 
methods section. The error bars represents SD from 6 repeats. (B) MALAT1 enhances proliferation of 
breast cancer cells. Cells described in (A) were seeded on 96 well plates and proliferation was measured 
under 0.1% serum condition. MALAT1 over expressing cells showed increased proliferative capacity even 
under starvation condition. The error bars represents SD from 6 repeats. (C) Cells described in (A) were 
seeded into soft agar and colonies were counted after 28 days. Graph represents the average and SD of 
number of colonies/well (N=3). Cells over expressing MALAT1 formed larger number of colonies in soft 
agar compared to empty vector. (D) Trypan blue exclusion assay of cells described in (A) to 0.1% serum 
and 1µM anisomycin for 24 hours. MALAT1 overexpression significantly inhibited anisomycin-induced cell 
death. (E) MALAT1 overexpression affects alternative splicing of SRSF1 targets. We found an increase in 
the inclusion of exon 5 of TEAD1 in cells overexpressing MALAT1, similar to the effect of SRSF1 
overexpression. We found increase in the anti-apoptotic isoforms containing exon 12A of the BIN1 gene 




Supplementary Figure 2.6  MALAT1 regulates the expression of genes involved in cell cycle and EMT. RT-
qPCR analyses to detect relative levels of mRNA of genes that are involved in cell cycle (A) and EMT (B) in 




Supplementary Figure 2.7  MALAT1 regulates the expression of genes involved in Cell cycle and EMT. RT-
qPCR analyses to detect relative levels of mRNA of genes that are involved in EMT in control and MALAT-




Supplementary Figure 2.8  MALAT1 regulates the expression of genes involved in EMT. RT-qPCR analyses 











CHAPTER 3. A NATURAL ANTISENSE LNCRNA CONTROLS BREAST CANCER PROGRESSION 
BY PROMOTING TUMOR SUPPRESSOR GENE MRNA STABILITY 
3.1 Introduction 
While more than 80% of the genome is transcribed to RNA, high throughput gene 
expression analyses reveal that only 2% of this transcribed RNA is translated into 
proteins. Current studies estimate that the human genome codes for several thousands 
of noncoding RNA genes [28-31]. Non-coding RNAs are grouped into different 
subclasses; from short non-coding transcripts like miRNAs and piRNAs (~20-30 
nucleotides long), to middle range ncRNAs like snRNAs and snoRNAs (~30-200 nts long), 
and finally the long non-coding RNAs (lncRNAs) (>200 bp in length). So far, the most 
studied class is miRNAs, which promote gene silencing either by inhibiting translation of 
target genes or by destabilizing the mRNAs [32, 33]. LncRNAs comprise the least studied, 
but most complex group of ncRNAs.  Unlike miRNAs, lncRNAs are very diverse with 
respect to their function, localization, abundance and interacting partners [47]. For 
instance, lncRNAs are able to form complex 3D secondary structures with the capacity 
to bind to proteins as well as to nucleic acids (DNA as well as RNA). This dual capacity 
renders lncRNAs as an ideal regulator in protein-nucleic acid network. The human 
genome is estimated to contain ~16000 lncRNAs 
[https://www.gencodegenes.org/stats/current.html#]. Based on the genome 
positioning, lncRNAs could further be grouped into subclasses, including NATs or natural 
antisense transcripts (~5521), lincRNAs or long intergenic non-coding RNAs (~7499), 
56 
 
sense intronic RNAs (~905), sense overlapping RNAs (~189), and processed transcripts 
(~544).   
Breast cancer (BC) is the most common cancer in women, underscoring a need for 
research and development of more efficient treatment strategies [11]. BC is a 
heterogeneous disease and comprises several subtypes based on the presence or 
absence of three hormone receptors; estrogen receptor (ER), progesterone receptor 
(PR) and human epidermal growth factor 2 (HER2). Based on the expressions of 
receptors, BC is categorized as Luminal A (ER positive and/or PR positive and HER2 
negative), Luminal B (ER positive and/or PR positive and HER2 negative or positive), 
HER2+ (ER and PR negative, HER2 positive) and triple-negative breast cancer 
(ER/PR/HER2 negative). The clinical outcome is worst for triple-negative breast cancer 
(TNBC) patients mainly due to lack of any of the three hormone receptors and, 
consequently, poor response to hormone-targeted therapies [12-15]. Therefore, there is 
an emergent need to investigate the molecular biology of the TNBC subtype in order to 
identify efficient prognostic and diagnostic markers.  
Current research on BC primarily focuses on the role of protein-coding genes in the 
disease progression. However, recent studies indicate that a significant number of 
lncRNAs show aberrant expression in BC patients (For review please see [178]). 
Abnormal expression of several lncRNAs is associated with chemoresistance in BC cells 
[179]. However, the underlying molecular mechanism remains to be determined for 
most cases. Mechanistic studies have indicated that some BC-deregulated lncRNAs play 
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crucial roles in disease pathology. For example, HOTAIR is known to negatively regulate 
the expression of a large number of protein-coding genes by recruiting repressive PRC2 
and LSD1 complexes to chromatin. HOTAIR is overexpressed in a significant number of 
BC patients, and is shown to act as a powerful predictor of metastasis [107]. We and 
others have demonstrated the involvement of MALAT1 lncRNA in breast cancer 
progression and metastasis [166, 180]. MALAT1 is overexpressed in a significant number 
of BC patients, and its depletion compromises both tumorigenic and metastatic 
properties of BC cells. In a mouse mammary carcinoma model, genetic loss or 
systematic depletion of MALAT1 in MMTV-PyMT resulted in slower tumor growth and 
reduction in metastasis [139]. In addition to HOTAIR and MALAT1, both of which 
promote oncogenesis, lncRNAs such as GAS5 are shown to act as tumor suppressors 
[181]. As of now, we understand the molecular action of only a handful of the several 
thousands of lncRNAs that show aberrant expression in BC patients. 
In order to identify lncRNAs that are deregulated during various stages of TNBC 
progression, we performed RNA-seq in an isogenic tumor progressive TNBC cell line 
series, and compared the expression of all of the annotated lncRNAs to a normal-like 
mammary epithelial cell line. We found that ~2900 lncRNAs showed aberrant expression 
in the metastatic BC cells. Among these lncRNAs, ~1000 of them are found to be natural 
antisense transcripts (NATs). Interestingly, we observed that several of these NATs are 
transcribed in opposite orientation to key oncogenic and tumor suppressor protein-
coding genes, and the expression of both sense and antisense transcripts is co-regulated 
in both TNBC cells and patient samples. Detailed analyses of one such NAT, PDCD4-
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antisense RNA 1 (PDCD4-AS1) in BC progression demonstrated that it regulates the 
expression of its sense protein-coding partner, PDCD4 (Programmed Cell Death 4) in cis. 
PDCD4, initially identified in a screen aimed to determine apoptosis-induced targets 
[86], is a well-established tumor suppressor gene [182]. We observed that the reduced 
levels of PDCD4-AS1 lncRNA in TNBC cells were correlated with reduced expression of 
PDCD4 in these cells. Further, we demonstrated that PDCD4-AS1 acted upstream of 
PDCD4 and induced PDCD4 expression by enhancing the stability of PDCD4 mRNA. Our 
studies have unearthed novel NAT-mediated post-transcriptional mechanisms 
controlling the expression of protein coding genes in cis.  
3.2 Results 
3.2.1 Hundreds of NATs display deregulated levels during breast cancer progression. 
Human breast carcinomas are thought to evolve via sequential genetic modifications 
from benign hyperplasia of mammary epithelial cells, through atypical ductal 
hyperplasia, to ducal carcinoma in situ (DCIS) and eventually to fully malignant tumors 
that possess the potential to metastasize into distant organs [134, 137, 183]. In order to 
understand the role of lncRNAs during various stages of breast cancer progression, we 
utilized a well-established isogenic mammary epithelial cell line-derived breast cancer 
progression model system [134, 137]. This system consists of multiple cancer cell lines 
of basal-like or TNBC subtype, all of which were initially derived from the spontaneously 
immortalized, non-tumorigenic mammary epithelial cell line, MCF10A [184]. The model 
system comprises of 4 isogenic cell lines, categorized as M1-M4 [134, 137].  M1 
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represents the normal, non-tumorigenic, immortalized MCF10A cells.  Transfection of 
MCF10A with activated T24-HRAS and selection by xenografting generated the M2 
(MCF10AT1k.cl2) cell line, which is highly proliferative and gives rise to premalignant 
lesions with the potential for neoplastic progression.  M3 (MCF10Ca1h) and M4 
(MCF10CA1a.cl1) were derived from occasional carcinomas arising from xenografts of 
M2 cells. M3 gives predominantly well-differentiated low-grade carcinomas on 
xenografting, while M4 gives rise to relatively undifferentiated carcinomas and colonizes 
to the lung upon injection of these cells into the tail vein [135, 138, 183, 185-187]. These 
lines represent progression through various stages of breast tumorigenesis, and 
recapitulate key steps that mimic the progression of breast cancer in vivo [185]. In 
addition, the common genetic background of these cells enables us to rule out the 
genetic variation behind the deregulated gene expression. We hypothesized that 
functional characterization of lncRNAs, especially those displaying differential 
expression among these cell lines, would help us to determine their roles in TNBC 
development.   
We cultured M1-M4 cells as three-dimensional (3D) acini-like structures in Matrigel for 
7-10 days, as 3D acini structurally and morphologically resemble in vivo acini of breast 
glands and lobules [141, 187].  We performed RNA-seq (Ribo-zero, poly A+) and 
analyzed the expression of 21198 genes in M1, M2, M3 and M4 cells (15816 protein 
coding and 5357 lncRNAs) (GENCODE Release 14 [GRCh37]) (Figure 3.1A). We identified 
transcripts, which were more than ±2 fold deregulated in M2, M3 and M4 compared to 
M1 cells. Since we were primarily interested in lncRNAs that show abnormal expression 
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during metastasis, we initially compared gene expression between M1 and M4 cells. 
~8563 genes (5668 protein coding and 2895 lncRNAs) showed ~2 fold change in their 
expression between M1 and M4 cells (Figure 3.1B). We noticed that ~50% of the 
expressed lncRNAs (2895 out of 5668 lncRNAs) showed alterations in their expression 
when we compared their levels between normal mammary epithelial versus metastatic 
BC cells, indicating the existence of a crucial regulatory network, controlling lncRNA 
expression during breast cancer progression. ~1541 out of the 2895 deregulated 
lncRNAs showed 2-fold upregulation in M4 cells (Figure 3.1C). On the other hand, 1354 
of lncRNAs displayed reduced levels in M4 compared to M1 cells. Further, we noticed 
that natural antisense transcripts (NATs) comprised one of the largest types of lncRNAs 
(991 out of 1895) that showed deregulation in M4 cells, only next to long intergenic 
lncRNAs (lincRNAs). (Figure 3.1D).   
NAT lncRNAs are typically enriched in the nucleus [29, 188, 189], and recent studies 
indicate that several of the NATs function in cis by regulating the expression of their 
sense partner protein-coding genes (for review please see [189-191]). To gain insights 
into the potential NAT-mediated cis-gene regulation in BC cells, we examined the status 
of co-regulated expression of 991 NATs and their protein-coding partner in M1 and M4 
cells. We observed that ~287 out of 991 deregulated NATs and their sense protein-
coding genes showed >2-fold change in their expression. Among them, 197 (~68%) NAT: 
mRNA pairs showed concordant pattern of deregulation (i.e., both sense/antisense pairs 
are up- or are down-regulated concordantly) and 90 (~32%) pairs exhibited discordant 
pattern of expression (Figure 3.1E-F).  To assess if these NATs potentially regulate the 
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expression of protein-coding genes that play crucial roles in BC progression, we 
determined the percentage of the sense protein coding genes in the sense: NAT pair 
that play well-established roles in cancer progression.  We compiled data sets from 
multiple sources to identify potential cancer-associated genes, that are involved in vital 
cellular processes such as cell cycle and Epithelial-to-Mesenchymal transition (EMT) 
(https://www.qiagen.com), (http://www.bushmanlab.org/links/genelists),  [166, 192].  
By this analysis, we identified >50 deregulated NAT: mRNA pairs (in M2, M3 and M4 
compared to M1) in which the protein coding genes have established roles in cancer 
progression (Figure 3.1F, Table 3.1). Furthermore, comparison of expression data of 
these NATs with ‘clinical survival in invasive breast carcinoma patient dataset’ (TCGA 
dataset, containing 105 normal samples and 814 breast tumors) revealed that the 
expression of 11 of these 54 NATs was well correlated with survival outcomes in BC 
patients  [193]. Thus, several of the BC deregulated NAT: sense protein-coding genes 
could potentially play vital roles in BC progression and survival.  
3.2.2 PDCD4-AS1 is downregulated during breast cancer progression, and its 
expression positively correlates with PDCD4 in BC cells and patients. 
To gain insights into the role of NATs in BC progression, we focused our attention on 
one NAT lncRNA, PDCD4-AS1 for the following reasons. PDCD4-AS1 is a NAT lncRNA, 
transcribed from the complementary strand of Programmed Cell Death 4 (PDCD4) gene 
(Figure 3.2A). PDCD4 is a known tumor suppressor gene that negatively regulates cell 
proliferation, neoplastic transformation and tumor invasion [194]. RNA-seq, RT-qPCR 
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and immunoblot analyses demonstrated reduced levels of PDCD4-AS1, PDCD4 mRNA 
and protein in M2, M3 & M4 cells compared to M1 (Figures 3.2B-D & S3.1A-B). 
Furthermore, PDCD4 and PDCD4-AS1 RNAs showed significant positive correlation with 
each other in breast cancer patient RNA data set (Figure 3.2E). Further, gene expression 
data from breast invasive carcinoma patients (TCGA data set) [193] revealed that 
PDCD4-AS1 showed lowest levels in basal-like or TNBC patients compared to Luminal A, 
Luminal B and HER2 subtypes (Figure 3.2F). Highest levels of PDCD4-AS1 were observed 
in stage Tis (stage 0, pre-cancer) breast samples compared to samples from the more 
aggressive stages of BC (Figure 3.2G). Finally, the elevated levels of PDCD4-AS1 were 
correlated with better survival rate in a cohort of BC patients (Figure 3.2H). Similar to 
PDCD4-AS1, TNBC patient samples showed lower levels of PDCD4 mRNA compared to 
normal mammary tissue (Figure 3.2I). Our results indicate that the levels of PDCD4-AS1 
and PDCD4 mRNA are co-regulated in BC cell lines and in BC patients. Low expression of 
PDCD4-AS1 in BC patient samples as well as better survival of patients with higher levels 
of PDCD4-AS1 implies that PDCD4-AS1, similar to its sense partner PDCD4, might 
function as a tumor suppressor. 
RNA-seq and RT-qPCR analyses in M1 cells determined PDCD4-AS1 as a multi-exonic 
(two exons), ~778 nts long polyadenylated transcript (Supplementary Figure3.1C & 3.2J). 
CPAT algorithm (Coding Potential Assessing Tool) identified PDCD4-AS1 as a noncoding 
RNA, as its coding potential score was relatively low and comparable to other well-
established lncRNAs such as MALAT1 (Supplementary Figure3.1D). Further, cellular 
fractionation followed by RT-qPCR revealed that PDCD4-AS1 was predominantly a 
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nucleus-enriched NAT lncRNA (Figure 3.2K). Finally, we determined the turnover rate of 
PDCD4-AS1 in M1 cells. RNA stability assay indicated that both PDCD4-AS1 transcript 
and its protein-coding partner PDCD4 mRNA displayed similar stability with both 
showing t1/2 of ~4hrs (Figure 3.2L). Our results identify PDCD4-AS1 as a nuclear-enriched, 
stable, polyA+ lncRNA.  
PDCD4 was initially identified as a tumor suppressor gene that was upregulated during 
serum starvation or cellular quiescence [86].  To test whether PDCD4-AS1 is also induced 
under conditions that activate PDCD4, we determined the expression of PDCD4 and 
PDCD4-AS1 in asynchronous and quiescent (serum-starved) M1 cells (Supplementary 
Figure3.2A and S3.2B).  RT-qPCR and immunoblot data revealed elevated levels of both 
PDCD4 (mRNA and protein) and PDCD4-AS1 RNA in quiescent cells (Supplementary 
Figure3.2C-D). Our results indicate that nuclear-enriched PDCD4-AS1 shows co-
regulated expression with its protein-coding partner PDCD4. 
3.2.3 PDCD4-AS1 negatively regulates cell migration of mammary epithelial cells.  
Since a lower level of PDCD4-AS1 RNA was associated with poor survival in breast cancer 
patients, and since it showed positive correlated expression with the tumor suppressor 
gene PDCD4 both in breast cancer cells and in patients, we evaluated whether PDCD4-
AS1 contributes to cancer-associated phenotypes. We stably depleted PDCD4-AS1 
transcripts by using three independent shRNAs targeting the sequences of PDCD4-AS1 
(exon 2) that were not overlapping with PDCD4 mRNA (Supplementary Figure3.3A-B) in 
non-tumorigenic mammary epithelial (M1) cells, and analyzed the migration potential of 
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control and PDCD4-AS1-depleted cells. M1 cells depleted of PDCD4-AS1 showed 
enhanced migration as observed by both transwell migration and wound healing assays 
(Figure 3.3A-D). Next, we overexpressed the full length PDCD4-AS1 in highly tumorigenic 
and metastatic M4 cells (M4 cells contain lower levels of endogenous PDCD4-AS1), and 
determined the effect on cell migration and long-term cell proliferation. We observed 
that PDCD4-AS1-overexpressing M4 cells showed significant reduction in their ability to 
migrate (Figures 3.3Ea-b), and displayed reduced proliferation (Figure 3.3Ec-d).  It is 
known that tumor suppressor PDCD4 inhibits cell proliferation [195]. Flow cytometric 
analyses revealed increased population of S and G2/M in PDCD4-depleted M1 cells 
(Figure 3.3F-G). Similarly, PDCD4-AS1-depleted M1 cells also showed increased 
population of S and G2/M cells (Figure 3.3H & I). Collectively, these results indicate that 
both PDCD4 and PDCD4-AS1 negatively regulate cell proliferation in human mammary 
cells.  
We observed that depletion of PDCD4-AS1 increased cell cycle progression, and 
migratory properties of M1 cells. Depletion of PDCD4 is also known to promote 
tumorigenic properties of human cells (For review please see [194]). Similar to what we 
observed upon depletion of PDCD4-AS1, PDCD4-depleted M1 cells also showed 
enhanced cell cycle progression and cell migration (Figures 3.3F-G & 3.3J-3.3K). Based 
on this, we hypothesize that PDCD4-AS1 negatively regulates tumorigenic properties of 
cells via modulating the expression of PDCD4. To determine whether PDCD4-AS1 acts 
upstream of PDCD4, we exogenously expressed of PDCD4 in PDCD4-AS1-depleted M1 
cells and tested the effect on cell migration phenotype (Supplementary Figure3.4A). 
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Trans-well migration assays revealed that M1 cells transiently overexpressing PDCD4 
alone did not show any significant change in their ability to migrate under in vitro 
conditions (data not shown), while PDCD4-AS1-depleted control cells displayed 
increased migration (Figures 3.3A-B & L [left and middle panels]). In contrast, 
overexpression of PDCD4 in cells that were stably depleted of PDCD4-AS1 rescued the 
enhanced migration, as these cells showed comparable levels of migration to control 
cells (Figures 3.3L-M; compare left and right panels in 3.3L).  Based on these results, we 
infer that PDCD4-AS1 negatively regulates cellular migration via PDCD4.   
3.2.4 PDCD4-AS1 promotes the stability of PDCD4 mRNA. 
To determine whether PDCD4-AS1 negatively regulates cell proliferation and cell 
migration by regulating the expression of PDCD4 in cis, we examined the level of PDCD4 
mRNA and protein in M1 cells stably depleted of PDCD4-AS1. We observed that PDCD4-
AS1-depleted cells showed consistent reduction in the levels of PDCD4 mRNA and 
protein (Figure 3.4A and 3.4B). In contrast, cells depleted of PDCD4 mRNA using gene 
specific siRNAs showed marginal increase in the levels of PDCD4-AS1 transcript (Figure 
3.4C and 3. 4D). In case of PDCD4-AS1-mediated regulation of PDCD4, we tested 
whether depletion of PDCD4-AS1 also alters the expression of other genes located in 
close genomic proximity. RT-qPCR analyses revealed that the expression of several other 
genes (BBIP1, SHOC2 and RBM20 [Figure 3.2A] that are located in genomic regions close 
to PDCD4-AS1/PDCD4 locus remained unaltered upon PDCD4-AS1 or PDCD4 depletion 
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(Supplementary Figure3.4B & S3.4C). These results imply that PDCD4-AS1 positively and 
specifically regulates the expression of its sense transcript.  
NATs could regulate the expression of their sense partner genes either by influencing 
their transcription or by modulating post-transcriptional processing of sense transcripts 
(for review please see [189]). To determine whether PDCD4-AS1 regulates the 
transcription of PDCD4 gene, we quantified the levels of nascent PDCD4 pre-mRNA in 
control and PDCD4-AS1-depleted cells by nascent RNA capture followed by RT-qPCR 
analysis. PDCD4-AS1-depleted M1 cells did not show any significant change in the total 
levels of nascent PDCD4 pre-mRNA, indicating that PDCD4 transcription remained 
unaffected in cells lacking PDCD4-AS1 (Figure 3.4E). Next, to test whether PDCD4-AS1 
influenced post-transcriptional processing of PDCD4 mRNA, we performed RNA stability 
assay. We treated control and PDCD4-AS1-depleted cells with an RNA polymerase II 
transcription inhibitor Falvopiridol (1µM), collected samples at several time points post 
drug treatment, and performed RT-qPCR analyses to determine the relative levels of 
PDCD4 mRNA. Control cells displayed a half-life of ~5 hrs for PDCD4 mRNA (Figure 3.4F). 
However, cells depleted of PDCD4-AS1 showed a significant reduction in the stability of 
PDCD4 mRNA, where the half-life was found to be ~2.5 hrs (Figure 3.4F). These results 
indicate that PDCD4-AS1 positively regulates the stability of PDCD4 mRNA.   
3.2.5 PDCD4-AS1 promotes the stability of PDCD4 mRNA by controlling the association 
of RNA-binding proteins to PDCD4 mRNA.  
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NATs are known to regulate the stability of their sense RNAs by forming RNA duplex 
[196, 197]. In the case of PDCD4-AS1/PDCD4 pair, the 5’end of both the transcripts, 
including exon 1 and part of intron 1, showed complete complementarity (Figure 3.5A; 
relative position within PDCD4-AS1 is highlighted in red lines). In addition, two other 
repetitive sequence elements located within exon 2 of PDCD4-AS1 show significant 
complementarity with sequences within the 3’UTR of PDCD4 mRNA.  A 258 nt long 
sequence (position 523-778 in exon 2) in PDCD4-AS1 shows 75% complementarity to a 
sequence within the 3’UTR PDCD4 mRNA (position 3164-3417). Besides this one, 
another shorter repeat of 103 nts long (position 204-306 of exon 2) in PDCD4-AS1 also 
shows 82% complementarity with the PDCD4 mRNA 3’UTR (position 3134-3236) 
(Supplementary Figure3.4D), indicating that multiple elements within PDCD4-AS1 and 
PDCD4 mRNA could complement to form RNA duplexes.  To determine whether PDCD4-
AS1 and PDCD4 RNA form RNA-duplex under in vivo conditions, we performed double-
strand RNase protection assays as reported earlier [56, 198]. RNaseA specifically cleaves 
the single-stranded RNAs but have no activity on double-stranded/duplex RNAs.  RNase 
protection assays confirmed the presence of stable RNA duplex between PDCD4-AS1 
and PDCD4 RNAs (Figure 3.5B). We used BACE1/BACE1-AS pairs as a positive control, 
which are known to form stable RNA duplexes [198] (Figure 3.5B). 
Next, we assessed if any of the specific sequence elements of PDCD4-AS1 play crucial 
roles in positively regulating the levels of PDCD4 mRNA. To this end, we generated full 
length and three mutant PDCD4-AS1 constructs (PDCD4-AS1-FL, PDCD4-AS1Δ208-778, 
PDCD4-AS1Δ477-778, PDCD4-AS1Δ1-207), each of which lacks specific sequence 
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elements that contain PDCD4 complementary sequences (Figure 3.5A). We expressed 
these constructs in control and endogenous PDCD4-AS1-depleted M1 cells and 
determined the effect on endogenous PDCD4 mRNA levels.  Interestingly, PDCD4-AS1-
FL, PDCD4-AS1Δ1-207 and PDCD4-AS1Δ477-778 expressed cells, which lacked 
endogenous PDCD4-AS1 rescued the levels of PDCD4 mRNA (Figure 3.5C). However, 
PDCD4-AS1Δ208-778 construct, which lacks the second exon, expressing cells failed to 
rescue the level of PDCD4 mRNA.  Based on the mutant analysis, we conclude that 
sequence elements within the exon 2 of PDCD4-AS1 play a crucial role in stabilizing 
PDCD4 mRNA.  
Our results indicate that sequences within the exon 2 of PDCD4-AS1, which potentially 
could form RNA duplexes with the 3’UTR of PDCD4 mRNA, play vital roles in enhancing 
the cellular levels of PDCD4 mRNA.  Association of RNA-binding proteins (RBPs) to 
3’UTRs is known to influence the cellular levels of PDCD4 mRNA. It was reported that 
RBPs such as HuR (human antigen R) and TIA1 (T-Cell intracellular antigen-1) recognize 
overlapping sequence within the 3’UTR of PDCD4 mRNA, and positively regulate the 
cellular levels of PDCD4 mRNA [91]. Hence, we sought to determine if PDCD4-AS1 
regulates the stability of PDCD4 mRNA by influencing the binding of these RBPs to 
PDCD4 mRNA 3’UTR. Analyses on the ENCODE eCLIP data set identified several potential 
binding sites of HuR and TIA1 on PDCD4 RNA [199] (data not shown). We performed 
RNA-immunoprecipitation (RIP) under crosslinking conditions using HuR or TIA1 
antibody followed by RT-qPCR to determine the interaction between endogenous HuR 
or TIA1 and PDCD4 mRNA in control and PDCD4-AS1-depleted cells. RIP assays in control 
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cells revealed that both HuR and TIA1 interacted with PDCD4 mRNA (Figures 3.5D-E). 
PDCD4-AS1-depleted cells showed reduced interaction between TIA1 and PDCD4 mRNA 
(Figures 3.5E). On the contrary, PDCD4-AS1-depleted cells showed significantly 
increased interaction between HuR and PDCD4 mRNA (Figure 3.5D). Altered interaction 
of TIA1 or HuR with PDCD4 mRNA in PDCD4-AS1-depleted cells was not due to overall 
changes in the total cellular levels of RBPs (Supplementary Figure3.4E and data not 
shown). Next, we examined if the depletion of HuR and TIA1 would affect the PDCD4 
mRNA levels in mammary epithelial cells. Contrary to the earlier report, [91], TIA1-
depleted mammary cells did not reduce the levels of PDCD4 mRNA (Supplementary 
Figure3.4 F-G). On the other hand, HuR depletion significantly increased PDCD4 mRNA 
and protein levels in control cells, indicating HuR negatively regulates the levels of 
PDCD4 mRNA (Figures 3.5F- G & S3.4H). Finally, depletion of HuR in M1 cells stably 
depleted of PDCD4-AS1 rescued the levels of PDCD4 mRNA and protein (Figure 3.5F-H), 
implying that PDCD4-AS1 influences PDCD4 mRNA stability by regulating HuR activity or 
HuR binding to PDCD4 mRNA. On the other hand, HuR depletion did not significantly 
alter the levels of PDCD4-AS1 RNA, indicating that HuR functions downstream of PDCD4-
AS1 in the PDCD4-AS1: PDCD4: HuR axis (Figure 3.5H). Thus, PDCD4-AS1 depletion 
enhances the binding of HuR with PDCD4 mRNA, and also destabilizes PDCD4 mRNA. It 
is likely that the reduced binding of TIA1 to PDCD4 mRNA in PDCD4-AS1-depleted cells is 
a consequence of enhanced interaction of HuR to the similar set sequence elements, 




To better understand the mechanism underlying breast cancer progression, we have 
attempted to determine the molecular function of differentially expressed lncRNAs both 
in M1-M4 breast cancer cell lines model and in TNBC patients. We focused our efforts 
on NATs and in particular, the roles played by PDCD4-AS1 in regulating the expression of 
PDCD4 tumor suppressor during BC progression. We have selected PDCD4-AS1/PDCD4 
pair for the mechanistic studies due to the following reasons. 1) Both PDCD4-AS1 and its 
coding partner, PDCD4 show concordant expression in BC cell lines and in TNBC patient 
samples. 2) Clinical survival data in BC patients revealed that similar to PDCD4 gene, 
lower expression of PDCD4-AS1 reduced overall patient survival, implying a tumor 
suppressor role for PDCD4-AS1. 3) Finally, PDCD4 is a tumor suppressor gene, and shows 
reduced expression in several types of cancer, including BC [182, 200-210].  PDCD4 is a 
homolog of eukaryotic translation initiation factor 4G (EIF4G), and by forming a complex 
with EIF4A1, PDCD4 reduces the interaction between EIF4A1 and EIF4G, thereby 
inhibiting EIF4A1’s helicase activity. PDCD4 negatively regulates the translation of 
several oncogenes such as cyclins, B-Myb and c-Myb [79, 80]. Moreover, PDCD4 
suppresses tumor cell migration by attenuating the expression of MMP9 (matrix 
metallopeptidase 9) via inhibiting AKT activation [211]. In addition, PDCD4 is induced 
during programmed cell death and promotes apoptosis [86]. Because of its critical role 
in several vital biological processes, its cellular level under normal physiological 
conditions is tightly regulated via several transcriptional and post-transcriptional 
regulatory mechanisms. For example, multiple microRNAs, including miR21 are known 
to negatively regulate the expression of PDCD4 [211-217]. RBPs such as HUR and TIA1 
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are also suggested to influence PDCD4 mRNA stability [91]. Our studies, demonstrating 
the role of PDCD4-AS1 in enhancing the cellular levels of PDCD4 adds another layer of 
complexity in PDCD4 regulation during BC progression.  
NATs are widely present in human genome, and on an average ~38% of genomic loci in 
cancer cells express sense: anti-sense pairs [192]. However, the NATs are expressed in 
much lower levels compared to sense transcripts, mostly enriched in the nucleus, and 
are suggested to influence the expression of their sense partners via cis-mediated gene 
regulation [192]. Similar to earlier observations, we observed aberrant expression of a 
significant percentage of NATs during BC progression [190-192]. Moreover, we observed 
that several of the NATs expressed from cancer-associated gene loci showed concordant 
expression with the oncogenic or tumor suppressor sense partner genes, and also 
displayed survival significance in patients. However, it is not clear whether all/most of 
these NATs play any role in regulating the expression of their sense partner in cancer 
cells, and/or whether they contribute to the molecular pathology of BC tumor 
progression and or metastasis.  
In the present work, we identified a role for PDCD4-AS1 in regulating the expression of 
PDCD4 in TNBC cells. We showed that PDCD4-AS1 depletion reduced the levels of 
PDCD4. PDCD4-AS1 depletion did not alter PDCD4 transcription significantly while it 
compromised the stability of PDCD4 mRNA. Further, we observed that PDCD4-AS1 
forms RNA duplex with PDCD4 mRNA, and PDCD4-AS1 negatively regulates the binding 
of AU-rich element binding protein HuR to PDCD4 mRNA. Finally, mutant analyses 
72 
 
revealed that the 3’end of PDCD4-AS1 contains sequence elements that control the 
cellular levels of PDCD4 mRNA. PDCD4-AS1 could promote the stability of PDCD4 mRNA 
by multiple mechanisms. It is possible that by forming RNA duplex, PDCD4-AS1 could 
prevent RNase-mediated degradation of PDCD4 mRNA, as observed in the case of 
FGFR3-AS1 [218]. Additionally, such RNA duplexes could prevent the binding of miRNAs 
to the 3’UTR of PDCD4 mRNA, thereby stabilizing the transcript. NAT such as BACE1-AS1, 
by forming RNA duplex with BACE1 mRNA in the cytoplasm, prevents the interaction of 
miRNAs with BACE1 mRNA, thereby stabilizing the mRNA [189, 198]. In the case of 
PDCD4, several miRNAs are known to recognize the sequence within the 3’UTR of 
PDCD4, which shows complementarity with the 3’end of PDCD4-AS1.  However, it is 
quite unlikely that PDCD4-AS1 promotes PDCD4 mRNA stability via preventing miRNA 
interactions due to the following reasons. Unlike BACE-AS1, PDCD4-AS1 is a low 
abundant RNA, and is predominantly localized in the nucleus. It is therefore unlikely that 
PDCD4-As1 could negatively influence the interactions between miRNAs and PDCD4 
mRNA in the cytoplasm.  
Alternatively, PDCD4-AS1 by forming RNA duplex with PDCD4 mRNA could influence the 
binding of RNA-binding proteins to PDCD4 mRNA. RNA-blast analyses revealed that 
specific sequences within the PDCD4-AS1 display elevated levels of complementarity 
with PDCD4 mRNA, and several of these regions could contribute to the formation of 
RNA duplex. Further, mutant rescue analyses revealed that exon 2 of PDCD4-AS1, which 
contains two discrete stretches of sequences that potentially could form RNA duplex 
with the 3’UTR of PDCD4 mRNA, is crucial for regulating the cellular levels of PDCD4 
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mRNA. It is possible that PDCD4-AS1 enhances the stability of PDCD4 mRNA by forming 
RNA duplex with specific sequences within the 3’UTR of PDCD4 mRNA, thereby 
influencing specific RBP: 3’UTR interactions. 
We observed that PDCD4-AS1 negatively regulates the association of 3’UTR interacting 
HuR with PDCD4 mRNA. HuR-depletion studies in M1 cells further identified HuR as a 
destabilizer of PDCD4 mRNA. HuR/ELAVL1 is a U-/AU-rich element interacting RBP that 
is known to regulate mRNA stability. (For review on HuR in breast cancer cells please see 
[219]. Several recent studies have described the role of HuR in destabilizing specific set 
of protein coding and noncoding RNAs [220, 221]. For example, HuR utilizes AUF1, Ago2 
or let-7 miRNA as co-factors to enhance the decay of p16(INK4) and MYC mRNAs [221, 
222].  We have recently reported that in mouse cells, double stranded RNA binding 
protein ADAR1 & 2 negatively regulates HuR- and RNA-deadenylase PARN-mediated 
degradation of a significant number of RNAs [223]. In this case, ADARs, by binding to the 
3’UTRs of RNAs limits the interaction between the RNA and decay promoting factors 
such as HuR and PARN complex.   
Earlier studies have reported that NATs by forming RNA duplex with regions of mRNA 
containing AU-rich sequences, influences that association of AU-rich interacting RNA 
decay factors, thereby controlling stability to the mRNA [224, 225]. For example, a NAT 
transcribed from the HIF1α locus destabilizes the mRNA of one of the HIF1α isoforms by 
binding to it and exposing the AU-rich sequence element within the 3’UTR of the HIF1α 
isoform mRNA [225].  On the other hand, an antisense transcript transcribed from the 
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Bcl2/IgH hybrid gene stabilizes the mRNA by covering the AU-rich sequence element 
[224]. Based on present studies, we hypothesize that HuR acts as a destabilizing factor 
of PDCD4 mRNA in BC cells, and PDCD4-AS1 stabilizes PDCD4 by limiting the interaction 
between PDCD4 mRNA and HuR and its associated RNA decay complex (Figure 5I). At 
present it is not clear how PDCD4-AS1 inhibits the association of HuR with PDCD4 
mRNA. We hypothesize that the formation of RNA duplex between PDCD4-AS1 and 
PDCD4 mRNA plays vital role in occluding the binding of HuR to the PDCD4 mRNA. In 
general, our studies have underscored the importance of a NAT lncRNA in BC 
progression via its role in regulating the expression of a tumor suppressor sense partner. 
Future studies will unravel mechanistic roles of thousands of other BC-deregulated 
lncRNAs in breast cancer biology.  
3.4 Material and Methods 
3D acini culture of M1-M4 cells: Acinar culture of M1-M4 cells was performed similar to 
three-dimensional culture of MCF10A cells described elsewhere [141]. Briefly, growth-
factor reduced Matrigel was used to coat multi-well plates. A single-cell suspension of 
each of the cell lines M1-M4 was prepared. M2-M2 cells were suspended in an assay 
medium containing growth medium (DMEM/F12 containing 2% Horse serum, 1 mg/ml 
hydrocortisone, 1 mg/ml cholera toxin, 10 mg/ml insulin, 10 ng/ml EGF, and 1% 
penicillin/streptomycin as well as 2.5% Matrigel dissolved in the medium. M3-M4 cells 
are prepared in the same way but omitting the EGF in the medium. The cells were 
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seeded at a concentration of 8000 cells/mL. Media was changed every fourth day. Cells 
were cultured for 8 days prior to harvesting. 
2D Cell culture: M1 and M2 cells were cultured in DMEM/F12 medium containing 5% 
horse serum supplemented with 100 U/mL penicillin, 100 µg/mL streptomycin, 20ng/mL 
EGF (epidermal growth factor), 0.5 µg/mL Hydrocortisone, 100ng/mL Cholera toxin, 10 
µg/mL insulin and 5% horse serum. M3 and M4 cells were cultured DMEM/F12 medium 
containing 5% horse serum supplemented with 100 U/mL penicillin, 100 µg/mL 
streptomycin.  
RNA-seq of M1-M4 cells and bioinformatics analysis: Single-end, Poly A+, ribo-zero RNA 
seq was performed in a depth of 80-100 million reads/sample. RNA-seq reads were 
aligned with the TopHap software (version 2.0.8b) to the human reference genome 
(hg19) downloaded from the UCSC Genome Browser. The parameters used with TopHap 
was “-i 50 –I 800000 –library-type fr-firststrand”. Transcripts expressions were 
estimated by Cufflinks version v.2.1.1 with the assembly guide from the gene annotation 
provided in the GENCODE release 14. Gene expression changes were quantified using 
Cuffdiff tool (included in the Cufflinks) with default parameters.  
RNA Extraction, RT PCR and quantitative PCR: Trizol reagent  (Invitrogen) was used to 
extract total RNA according to manufacturer’s protocol. The concentration was 
measures using Nanodrop instrument (ThermoFisher SCIENTIFIC). RNA was treated with 
RNase-free DNase I (Sigma, USA) and cDNA was synthesized from RNA using High 
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capacity reverse transcription kit (Applied Biosystem). Quantitative PCR was carried out 
by StepOne Plus system (Applied Biosystem).  
Knockdown/overexpression experiments: PDCD4 depletion was achieved by transfection 
with siRNA against GL3 (control) or siRNAs against PDCD4 (40-50 nM con, IDT) for one 
round using Lipofectamine RNAiMax reagent (Invitrogen). TIA1 depletion was 
performed using siRNA purchased from IDT. HuR depletion was carried out using siRNA 
as used in [226]. PDCD4-AS1 knockdown was performed by shRNA lentivirus-mediated 
transduction.  For overexpression, full-length PDCD4 was purchased as pGEX6p1-hPdcd4 
from Addgene [227] and cloned into pCGT vector. Full length PDCD4-AS1 and mutants 
were purchased as gblocks from IDT technology, cloned and expressed in pCGT vector, 
empty vector acted as control.  
Cell migration assay: We used transwell migration chambers (Corning, Cat# 354578) and 
to perform migration assays as previously explained [166]. Briefly, cells were starved in 
a serum-free medium, which was then trypsinized , counted and seeded in serum-free 
medium in transwell chamber (8µM). We placed the cell containing chambers into a 
well containing serum (24-well plate). Cells were kept in incubator 37 C, 5% CO2 
overnight. Migrating cells were stained by Crystal Violet 0.05% and counted the day 
after.  
Wound healing assay: The wound was created by 200 µl filter tips. After washing with 
PBS, serum-free medium was added to cells in order to discourage the cell proliferation. 
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Images were taken at Day0, 1, 2 and 3 after wound creation to monitor the wound 
healing. 
Nascent RNA capture assay: Click-iT Nascent RNA capture kit (Invitrogen, Cat # C10365) 
was used to isolate nascent RNA following the product’s protocol. Then quantitative RT-
qPCR was performed using gene-specific primers. 
RNA stability assay: Cells were treated with Flavopiridol (1M) and were collected at 
different time points post treatment. RNA extraction and RT-qPCR was carried out as 
explained above. 
RNA immunoprecipitation (RIP): RIP was conducted as described before [59, 223]. 
Briefly, RNA-Protein interactions were reversibly crosslinked by formaldehyde in cells. 
Cells were lysed and lysate was immunoprecipitated using Anti-HUR (HuR (3A2): sc-
5261, Santa Cruz Biotechnology) and Anti-TIA1 antibody (TIA-1 (G-3): sc-166247, Santa 
Cruz Biotechnology). After RIP, we reversed cross-link and RNA extraction using Trizol LS 
(Invitrogen). DNase I treatment, reverse transcription and qPCR was performed as 
described above. 
Nuclear and cytoplasmic fractionation: As explained in [223], we washed cells with PBS 
and lysed in RSB buffer (10 mM Tris-HCl pH7.4, 100 mM NaCl, 2.5 mM MgCl2, RNase 
Inhibitor) supplemented with Digitonin (8  g/ml) (D141-100MG, Sigma-Aldrich, USA) for 
10 min on ice. Lysate was centrifuged at 2000 rpm, 4◦C, 10 min. Supernatant was 
collected as cytoplasmic fraction and RNA was extracted from with Trizol LS (Invitrogen). 
The pellet included the nuclear fraction. We washed the nuclear pellet with RSB-
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Digitonin solution one more time and then RNA was extracted using Trizol reagent 
(Invitrogen). 
Poly(A) fractionation: Poly(A) fractionation was performed as previously described [56]. 
In brief, NucleoTrap mRNA kit (Clontech) was used to fractionate Poly(A) plus and 
Poly(A) minus fractions following by extraction, RT and qPCR. 
Double-strand RNase Protection Assay: The experiment was performed as described 
previously [56]. Cells were washed with PBS and lysed in lysis buffer (10 mM Tris pH 7.4, 
3 mM CaCl2, 2 mM MgCl2, and 0.7% NP-40). Cell lysate was passed through needle 
(27.5 gauge) five times and then incubated on ice for 10 minutes. The final solution was 
adjusted to DNase I (Sigma) 12.5 units/ml and 125 mM NaCl. The lysate was divided to 
two fractions. To one fraction RNase A (QIAgen) and the other fraction RNAse Inhibitor 
was added to final concentrations of 200 ng/ml and 250 units/ml; respectively. Then, 






  NAT↓ - PC↓ NAT↑ - PC↑ 
NAT↓ - 
PC↑ 
NAT↑ - PC↓ 
M4/M1 CD248, CEBPA, FOXC2, 
GRHL2, ID2, JDP2, 
LEPREL1, MEIS1, 
MRVI1, MYCL, NEBL, 
PDCD4, PDX1, RFX2, 
RFX5, SEMA3F, SYNE1, 
TBX2, TCF4, THBS3, 
TMEFF2, TP73, UNC5B, 
WISP2, WNT5A, ZEB2, 
ZNF224* 
CDH2, CORO1A, EPHA2, 
FDPS, FLNB, GSN, HMGA2, 
HOXC11, INHBA, ITGB3, 
LASP1, LIF, NFIB, NRP1, 
PAX8, PTHLH, RNF157, 










M3/M1 ANK3, CD248, CEBPA, 
DSC2, FOXC2, GRHL2, 
HOXC13, ID2, JDP2, 
LMO3, MYCL, PDCD4, 
SEMA3F, ST7, TMBIM4, 
TP73, UNC5B, WNT5A 
42987*, ADAMTS18, CCND2, 
CDH2, CORO1A, DLG3, E2F5, 
GSN, HAS2, IL21R, INHBA, 
ITGA6, ITGB3, LEPREL1, LIF, 
LSAMP, MST1R, NFIB, NGFR, 
NRP1, PLXNC1, POU2F2, 
RARA, RBBP8*, RNF157, 
ROR1, SMPDL3B, SRPX, 











M2/M1 CDK6, CEBPA*, 
COL4A3, DLC1, GRHL2, 
HOXC13, ID2, MEIS1, 
PAX8, UNC5B, WNT5A 
CA2, COL16A1, CTGF, ELN, 
GSN, KSR1, NFIB, NGFR, 
PATZ1, PLXNC1, PTHLH, 
RBBP8, RNF157, STEAP3, 








NAT: Natural Antisense Transcript , PC: Protein Coding gene  
Deregulated cancer-associated PC is shown and NATs are not shown in this table.  
* There are more than one deregulated NAT present at the locus of these PC genes   
 
Table 3.1 Deregulated cancer-associated PC with corresponding deregulated NAT in M2, M3 and M4 






Figure 3.1 Natural Antisense Transcripts show aberrant expression during breast cancer progression. A) 
Total number of genes analyzed in M1-M4 cells. B) Number of deregulated ncRNA and protein-coding 
RNA genes in M4 cells compared to M1 cells. C) Number of deregulated lncRNA genes in M4 compared to 
M1 cells. D) Different classes of aberrantly expressed lncRNA genes in M4 compared to M1 cells. E) 
Number of sense/antisense pairs that show concordant or discordant pattern of expression in M4 
compared to M1 cells. F) Heatmap representation presentation of deregulated sense/antisense pairs in 




Figure 3.2 PDCD4-AS1 is a stable nuclear lncRNA that shows concordant pattern of expression with its 
coding partner PDCD4. A) Schematic representation of PDCD4/PDCD4-AS1 gene locus. B) PDCD4-AS1 RNA 
level measured by RT-qPCR in M1- M4 TNBC cells. C) PDCD4 mRNA level measured by RT-qPCR in M1- M4 
TNBC cells. D) Immunoblot analysis shows the relative levels of PDCD4 protein in M1- M4 cells. E) 
Correlation analysis between PDCD4 and PDCD4-AS1 in TCGA breast cancer dataset, analyzed by TANRIC 
platform. F) PDCD4-AS1 RNA level in different subclasses of breast cancer patients, analyzed by TANRIC 
platform. G) PDCD4-AS1 RNA level in different stages of breast cancer patients analyzed by TANRIC 
platform. H) Kaplan–Meier analysis to depict the survival rate in TCGA breast cancer patients with high 
and low levels of PDCD4-AS1, analyzed by TANRIC platform. I) PDCD4 mRNA level in TNBC patients 
compared to normal breast samples. RT-qPCR analyses in (J) poly A
+
 and poly A
-
 and (K) nuclear and 
cytoplasmic fractionated RNA from M1 cells. L) RT-qPCR to quantify the stability of PDCD4-AS1 and PDCD4 
mRNA using RNA from M1 cells treated with Flavopiridol (1M) for several time points (0, 1,2,4 and 6 hrs). 
Error bars in (B, C, J, K & L) represent mean ± SEM of N≥3 independent experiments (biological replicates). 




Figure 3.3 PDCD4-AS1 negatively regulates cell proliferation and migration. A-B) Transwell migration 
assay in control and PDCD4-AS1 depleted M1 cells. C-D) Wound healing assay in control and PDCD4-AS1 
depleted M1 cells. Images were taken at Day 0, 1, 2 and 3 after wound creation; the magnified image of 
Day 3 in control and PDCD4-AS1 depleted cells is shown in the figure C. Ea,c) Transwell migration assay in 
M4 cells that are overexpressing PDCD4-AS1. Eb,d) Long-term anchorage-dependent colony formation 
assay in M4 cells upon PDCD4-AS1 overexpression. F-G) Cell cycle flow cytometry in control and PDCD4 
depleted M1 cells. H-I) Cell cycle flow cytometry in control and PDCD4-AS1 depleted M1 cells. J-K) 
Transwell migration assay in control and PDCD4 depleted M1 cells. L-M) Transwell migration assay in 
control and PDCD4-overexpressing M1 cells that are depleted of PDCD4-AS1 (AS-sh3). Error bars in (B, D, 
Eb, Ed, G, H, K & M) represent mean ± SEM of N≥3 independent experiments (biological replicates). 




Figure 3.4 PDCD4-AS1 promotes the stability of PDCD4 mRNA. A)  PDCD4 and PDCD4-AS1 RNA level 
measured by RT-qPCR in control and PDCD4-AS1 depleted-M1 cells. B) PDCD4 protein level in control and 
PDCD4-AS1 depleted M1 cells. C) PDCD4 and PDCD4-AS1 RNA level measured by qPCR in control and 
PDCD4 depleted M1 cells. D) PDCD4 protein level in control and PDCD4-depleted M1 cells. E) Nascent RNA 
assay in control and PDCD4-AS1-depleted M1 cells. F) RT-qPCR to quantify PDCD4 mRNA stability assay 
using RNA from control and PDCD4-AS1 depleted M1 cells treated with Flavopiridol (1M) for several time 
points (0, 1,2,3 and 6 hrs). Error bars in (A, D, E & F) represent mean ± SEM of N≥3 independent 
experiments (biological replicates). *P<0.05, ** P< 0.01 and ***P<0.001 using Student’s t test. N.S. 




Figure 3.5 PDCD4-AS1 forms RNA duplex with PDCD4 mRNA, and regulates the association of RNA 
decay factors to PDCD4 mRNA. A) Schematic representation of PDCD4-AS1/PDCD4 gene locus, and 
PDCD4-AS1 full-length and mutants that are used for rescue assay. Red bars show regions of PDCD4-AS1 
with potential complementarity to PDCD4 mRNA. Shaded region represent the minimum region within 
PDCD4-AS1 that is required for stabilizing the level of PDCD4 mRNA. B) RT-qPCR analyses followed by 
RNase protection assay. GAPDH is used as negative control where as BACE-As1 is used as positive control. 
C) RT-qPCR to quantify the relative levels of PDCD4 mRNA in PDCD4-AS1-depleted M1 cells 
overexpressing vector alone or other PDCD4-As1 constructs. D) RT-qPCR to quantify the levels of PDCD4 
mRNA post HuR-RIP in control and PDCD4-AS1 depleted M1 cells. E) RT-qPCR to quantify the levels of 
PDCD4 mRNA post TIA1 RIP in control and PDCD4-AS1 depleted M1 cells. F) RT-qPCR to detect PDCD4 
mRNA level in HuR-depleted control and PDCD4-AS1-depleted cells. G) PDCD4 protein level in HuR-
depleted control and PDCD4-AS1-depleted cells. H) RT-qPCR to detect PDCD4-AS1 RNA level in HuR-
depleted control and PDCD4-AS1-depleted cells. I) Proposed model showing the mode of action of 
PDCD4-AS1 in promoting the stability of PDCD4 mRNA by attenuating the association of HuR to the 3UTR 
of PDCD4 mRNA.  Error bars in (B, C, D, E, F & H) represent mean ± SEM of N≥3 independent experiments 






3.7 Supplemental Figures 
 
Supplementary Figure 3.1 PDCD4-AS1 lncRNA and PDCD4 show reduced expression during BC 
progression. A) RNAseq signals, corresponding to PDCD4-AS1 in UCSC browser in M1, M2, M3 and M4 
cells. Signal intensity is adjusted (0-20). B) RNAseq signals, corresponding to PDCD4 in UCSC browser in 
M1, M2, M3 and M4 cells. Signal intensity is adjusted (0-1000). C) RNAseq signal in M1, corresponding to 
PDCD4-AS1 annotation in UCSC browser. D) Coding probability of several RNA, including PDCD4-As1, 




Supplementary Figure 3.2 PDCD4 and PDCD4-AS1 show induction during cellular quiescence. A) Flow 
cytometry analyses of Asynchronous and quiescent M1 cells. B) Percentage of cells at different cell cycle 
stage in asynchronous and quiescent M1 cells, observed by flow cytometry analyses. C) PDCD4 and 
PDCD4-AS1 relative RNA levels in asynchronous and quiescent M1 cells. D) PDCD4 protein levels in 
biologically triplicate asynchronous and quiescent M1 cells. Error bars in (B & H) represent mean ± SEM of 




Supplementary Figure 3.3 A) Schematic representation of PDCD4-AS1/PDCD4 gene locus, showing the 
position of three shRNAs (sh1-3) utilized to stably deplete PDCD4-AS1. B) RT-qPCR reveals significant 
depletion of PDCD4-AS1 RNA in cells stably transfected with PDCD4-AS1 shRNAs. Error bars in B represent 
mean ± SEM of N≥3 independent experiments (biological replicates). *P<0.05, ** P< 0.01 and ***P<0.001 




Supplementary Figure 3.4 PDCD4-AS1 regulates the stability of PDCD4 mRNA by influencing the 
association of RNA decay factors. A) PDCD4 immunoblot in cells transfected with vector or PDCD4 cDNA 
containing plasmid. B) RT-qPCR to quantify the relative levels of SHOC2, BBIP1, and RBM20 mRNA in 
control and PDCD4-AS1 depleted M1 cells. C) RT-qPCR to quantify the relative levels of SHOC2, BBIP1, 
RBM20 mRNA levels in control and PDCD4 depleted M1 cells. D) PDCD4 mRNA dot plot alignment with 
non-spliced PDCD4-AS1 showing three potential complementarity regions. E) Immunoblot to detect TIA1 
protein in control and PDCD4-AS1 depleted M1 cells. F) TIA1 protein and G) PDCD4 mRNA level in control 
and TIA1 depleted M1 cells. H) Immunoblot to detect HuR protein in control and HuR-depleted M1 cells. 
B”-U2snRNP is used as a loading control in Figs A, E, F, and H. Error bars in (B, C & G) represent mean ± 
SEM of three independent experiments (biological replicates). 
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CHAPTER 4. CONCLUSION 
Breast cancer is still one of the leading causes of death in women worldwide [92]. 
According to Gencode Version 27 (January 2017 freeze, GRCh38) - Ensembl 90, the 
human genome contains 58288 genes, including 19836 protein-coding genes and non-
protein coding genes such as 15778 lncRNA genes and 1881 miRNAs. 
[https://www.gencodegenes.org/stats/current.html#]. LncRNAs constitute the largest 
class of non-coding RNAs, and could further be grouped into subclasses, including NATs 
or natural antisense transcripts (5521), lincRNAs  or long intergenic non-coding RNAs 
(7499), sense intronic RNAs (905), sense overlapping RNAs (189), and processed 
transcripts (544).   
In addition to deregulation of protein-coding genes, deregulation of non-coding RNAs 
like lncRNAs has been reported in many tumors [45]. Considering the tissue-specific 
expression, lncRNAs could have potential implication in cancer diagnoses and 
treatment.  Furthermore, long non-coding RNAs are less conserved among mammalian 
species compared to protein-coding genes and lncRNAs could be the missing link that 
why an animal model like mouse does not always predict the human response to each 
particular therapy. To investigate the cellular and molecular signature associated with 
tumor progression, we studied the role of long non-coding RNAs in breast cancer, 
focusing on the role of MALAT1 and PDCD4-AS1 in TNBC sub type of BC.  
MALAT1 is a long intergenic non-coding RNA which is ~8kb long. MALAT1 is very 
abundant and mostly localizes to nuclear speckle and is known to function in mRNA 
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processing, including pre-mRNA alternative splicing [59]. In this study, we showed the 
involvement of MALAT1 in cell proliferation, anchorage independent growth, migration 
and invasion in TNBC cell lines. We demonstrated that MALAT1 depletion reduces the 
expression of several cell cycle and metastasis-associated genes, which consequently 
decreases the cell proliferative, migratory and invasive potential in TNBC cells. 
Furthermore, patient survival data suggest that MALAT1 level in lymph node negative 
patients could be identified as an indicator for future metastasis in HER2+ and TNBC 
patients. Lymph node negative patients usually are not prescribed for follow-up 
chemotherapy. But our study proposes that elevated levels of MALAT1 could be 
identified as a ‘red flag’ in the lymph node negative HER2+ and TNBC patients, 
predicting a higher likelihood of tumor recurrence and metastasis compared to patients 
with lower level of MALAT1. 
To further study the role of lncRNAs in breast cancer progression, we determined the 
role of a natural antisense transcript called PDCD4-AS1 in TNBC patients. First, we 
examined the PDCD4-AS1 expression in triple negative breast cancer patients and cell 
lines. PDCD4-AS1 is down-regulated in patients compared to normal, and the same 
pattern was also observed in the TNBC tumor progression cell line series M1, M2, M3 
and M4. Based on the expression pattern, PDCD4-AS1 fits in the class of tumor 
suppressor lncRNAs. PDCD4-AS1 low level is correlated with worse survival rate in 
breast cancer patients based on TCGA database and TANRIC analysis. In addition, in 
different stages of breast invasive carcinoma, PDCD4-AS1 has the highest level in stage 
Tis (stage 0 or pre-cancer) and is down regulated in the more aggressive stages of the 
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cancer. In breast cancer patients, PDCD4-AS1 lowest expression is observed in TNBC 
subtype. PDCD4-AS1 is a low copy transcript, poly-adenylated and contains two exons. 
The first exon of PDCD4-AS1 partially overlaps with the first intron of PDCD4 gene.  
PDCD4 is a known tumor suppressor gene as its down-regulation is associated with 
tumor progression and metastasis in different types of cancers [194]. PDCD4 is known as 
a translational inhibitor through its interaction with EIF4A by inhibiting EIF4A helicase 
activity and consequently precluding translation of mRNAs with highly structured 5’UTR 
[79]. However, a very recent study showed that EIF4A existed far in excess to PDCD4 in 
both normal and tumor lung cell lines [228]. Thereby, PDCD4-EIF4A interaction did not 
exhaust free EIF4A pool in the cell. This study suggested that PDCD4 interaction with 
specific mRNA targets is critical for its function as a tumor suppressor. The new mode of 
action proposed by this work demonstrated that PDCD4 interacts with the mRNA in the 
nucleus and then PDCD4-mRNA complex is shuttled to cytoplasm. Then, PDCD4-mRNA 
RNP complex interacted with EIF4A in cytoplasm; the mRNA-PDCD4-EIF4A complex is 
not permissive for translation [228]. No matter what the mode of action is, PDCD4 lower 
expression is associated with increased translation of genes that promotes cell 
proliferation, mobility, and invasion and anti-apoptotic pathways [79, 194].  
In this study, we showed PDCD4-AS1 depletion decreased PDCD4 at both mRNA and 
protein levels. Specifically, we elucidated that PDCD4-AS1 depletion increases the HuR 
binding to PDCD4 mRNA, further compromising the stability of PDCD4 mRNA.  
92 
 
In this thesis, we studied the involvement of two different lncRNAs in breast cancer 
progression. MALAT1 is a highly abundant intergenic lncRNA, which widely influences 
the gene expression pattern in cells and promotes cancer cell proliferation and 
metastasis. On the other hand, PDCD4-AS1 is a low copy antisense lncRNA, which 
negatively regulates cancer progression by cis-regulating the expression of a tumor 
suppressor gene PDCD4. This result further highlighted the critical involvement of 
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